



## **AmeriHealth Medicare PPO 2024 Utilization Management Criteria: Prior Authorization**

### **PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN**

This document was updated on 3/19/2024. For more recent information or other questions, please contact our Member Help Team at 1-866-569-5190 or, for TTY/TDD users, 711, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit [www.amerihealthmedicare.com](http://www.amerihealthmedicare.com) to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means AmeriHealth Medicare PPO. When it refers to “plan” or “our plan,” it means AmeriHealth Medicare Core PPO, AmeriHealth Medicare Enhanced PPO, AmeriHealth Medicare Secure PPO, and AmeriHealth Medicare Ultimate PPO.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2025, and from time to time during the year.

AmeriHealth Medicare coverage issued by AmeriHealth Insurance Company of New Jersey.

AmeriHealth Insurance Company of New Jersey offers PPO plans with a Medicare contract. Enrollment in AmeriHealth PPO plans depends on contract renewal.

Y0041\_H5361\_AH\_24\_113765\_C

AH13548(04/24)

## There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this “utilization management.” These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug. Drugs that require prior authorization are listed in this document.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require step therapy are listed in *2024 Utilization Management Criteria: Step Therapy*.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have quantity limits are listed in the *AmeriHealth Medicare PPO Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting [www.amerhealthmedicare.com](http://www.amerhealthmedicare.com).

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

## How to use this document

This document, along with *2024 Utilization Management Criteria: Step Therapy*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note “PA” in the “Requirements” column of the *AmeriHealth Medicare PPO Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 209. The restriction information includes:

- **Prior Authorization**
  - Covered uses
  - Exclusion criteria
  - Required medical information
  - Age restrictions
  - Prescriber restrictions
  - Coverage duration
  - Other criteria

Be sure to read all the information listed for your affected drug. If you have any questions or need assistance with the information contained in this document, please call our Member Help Team: AmeriHealth Medicare PPO at 1-866-569-5190 or, for TTY/TDD users, 711.

# ABUSE DETERRENT OPIOID

---

## Products Affected

- *hydrocodone bitartrate er oral capsule extended release 12 hour*
- XTAMPZA ER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of one of the following: (1) Prior use of TWO generic opioids OR (2) BOTH of the following: (a) there is a history of or a potential for drug abuse among the individual or a member of the individual's household AND (b) documentation of current patient-prescriber opioid treatment agreement
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACTHAR HP

## Products Affected

- CORTROPHIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(All Indications): Scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins or porcine origin, or where congenital infections are suspected in infants. OR Administration of live or live attenuated vaccines in members receiving immunosuppressive doses of H.P. Acthar Gel.
<b>Required Medical Information</b>	Part D is medically necessary when ONE of the following is present: (1) Infantile Spasms (IS): (A) Diagnosis of IS. (2) Acute Exacerbation of Multiple Sclerosis (AEMS): (A) Diagnosis of an AEMS, (B) Currently receiving maintenance treatment for MS (e.g. Avonex, Betaseron, Copaxone, Tecfidera, etc.), (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (3) Acute Exacerbation of Psoriatic Arthritis (AEPsA): (A) Diagnosis of an AEPsA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (4) Acute Exacerbation of Rheumatoid Arthritis (AERA): (A) Diagnosis of an AERA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (5) Acute Exacerbation of Juvenile Rheumatoid Arthritis (AEJRA): (A) Diagnosis of an AEJRA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (6) Acute Exacerbation of Ankylosing Spondylitis (AEAS): (A) Diagnosis of an AEAS, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (7) Nephrotic Syndrome (NS): (A) Diagnosis of NS, (B) Proteinuria greater than 3.5g/ 24 hours, (C) serum albumin less than 3 mg/dL, (D) Peripheral edema. (F) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (8) Systemic Lupus Erythematosus (SLE): (A) Diagnosis of SLE, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone).
<b>Age Restrictions</b>	(IS): Member is younger than 2 years of age. (MS): Member is 18 years of age and older. (All Other Indications): Member is 2 years of age and older

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(IS): Prescribed by or in consultation with an neurologist or neonatologist. (All Other Indications): Prescribed by or in consultation with a neurologist, rheumatologist, nephrologist, pulmonologist, ophthalmologist, dermatologist, allergist, immunologist.
<b>Coverage Duration</b>	(IS): 1 year (All Other Indications): 1 month
<b>Other Criteria</b>	Subject to Part B vs Part D review. (9) Systemic Dermatomyositis (SDM): (A) Diagnosis of SDM (polymyositis), (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (10) Severe Erythema Multiforme (SEM): (A) Diagnosis of SEM, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (11) Stevens-Johnson Syndrome (SJS): (A) Diagnosis of SJS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (12) Serum Sickness (SS): (A) Diagnosis of SS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (13) Inflammatory Ophthalmic Disease (IOD): (A) Diagnosis of IOD, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (14) Symptomatic Sarcoidosis (SSD): (A) Diagnosis of SSD, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (ALL INDICATIONS): Dosing is in accordance with the United States Food and Drug Administration (FDA) approved labeling
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACUTE HAE AGENTS

## Products Affected

- BERINERT SYRINGE
- *icatibant acetate subcutaneous solution prefilled syringe*
- SAJAZIR SUBCUTANEOUS SOLUTION PREFILLED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when the following inclusion criteria is met: Hereditary Angioedema (HAE): (1) Used for the treatment of acute abdominal, facial or laryngeal attacks of HAE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HAE): Prescribed by or in consultation with an allergist or immunologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACUTE SEIZURE ACTIVITY AGENTS

---

## Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescriber is a neurologist/epilepsy specialist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADALIMUMAB PREFERRED PRODUCTS

## Products Affected

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER
- YUFLYMA (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.4ML
- YUFLYMA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 40 MG/0.4ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, AS, JIA, PsA, PsO, CD, UC, HS, UV): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g., tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g., methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Juvenile Idiopathic Arthritis (JIA): (1) Diagnosis of moderate to severe JIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD: (e.g., methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO.
<b>Age Restrictions</b>	Member is within the age group listed in the FDA labeling for the indication
<b>Prescriber Restrictions</b>	(RA, JIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (PsO, HS): Prescribed by or in consultation with a dermatologist. (CD, UC): Prescribed by or in consultation with a gastroenterologist. (UV): Prescribed by or in consultation with a rheumatologist or ophthalmologist.
<b>Coverage Duration</b>	Indefinite



PA Criteria	Criteria Details
<b>Other Criteria</b>	Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g., corticosteroid, methotrexate, azathioprine or 6-mercaptopurine). Ulcerative Colitis (UC): (1) Diagnosis of UC. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g., corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine). Hidradenitis Suppurativa (HS): (1) Diagnosis of HS. Uveitis (UV)(Initial): (1) Diagnosis of non-infectious intermediate, posterior, or pan-uveitis. (2) Inadequate response or inability to tolerate corticosteroids and at least one immunosuppressive drug (e.g., azathioprine, cyclosporine, methotrexate, mycophenolate).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADBRY

---

## Products Affected

- ADBRY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of moderate to severe AD (2) inadequate response or inability to tolerate BOTH of the following: (a) one topical steroid (medium potency or higher) AND (b) topical tacrolimus.
<b>Age Restrictions</b>	(AD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADEMPAS

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH, CTEPH) (Initial, Reauth): Concurrent use of phosphodiesterase inhibitors, nitrates or nitric oxide donors, pregnancy, concurrent use with other soluble guanylate cyclase stimulators (e.g. Verquvo)
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II - IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (initial): (1) Diagnosis of persistent/recurrent CTPH (WHO Group 4) after surgical treatment or inoperable CTEPH.
<b>Age Restrictions</b>	(PAH, CTEPH) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PAH, CTEPH) (initial, Reauth): Prescribed by or in consultation with a pulmonologist or cardiologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth):12 months
<b>Other Criteria</b>	(PAH, CPTEH) (Reauth): Stabilization or improvement.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AIMOVIG

## Products Affected

- AIMOVIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Documentation of concomitant use with another injectable CGRP inhibitor.
<b>Required Medical Information</b>	Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4-week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine. OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine.
<b>Age Restrictions</b>	(Migraines)(Initial, Reauth): Member 18 years of age or older
<b>Prescriber Restrictions</b>	(Migraines)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist
<b>Coverage Duration</b>	(Migraines)(Initial): 6 months (Migraines)(Reauth): 12 months
<b>Other Criteria</b>	(Migraines)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ALLERGEN SPECIFIC IMMUNOTHERAPY (SL)

## Products Affected

- GRASTEK
- ODACTRA
- ORALAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial): Deny with documentation of any of the following: (1) Severe, unstable or uncontrolled asthma (2) History of eosinophilic esophagitis
<b>Required Medical Information</b>	(Initial): (1) Member has a positive skin test or in vitro test for the listed pollen-specific IgE antibody. (2) Inadequate response or inability to tolerate an intranasal corticosteroid and an oral or intranasal antihistamine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with an allergist or immunologist.
<b>Coverage Duration</b>	(Initial, Reauth): Remainder of contract year
<b>Other Criteria</b>	(Reauth): (1) Member has experienced improvement in the symptoms of their allergic rhinitis or a decrease in the number of medications needed to control allergy symptoms
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMPYRA

## Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	MS (Initial): Deny if member has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min)
<b>Required Medical Information</b>	Multiple Sclerosis (MS) (Initial): (1) Diagnosis of multiple sclerosis. (2) Confirmation that member has difficulty walking. (3) Inadequate response or inability to tolerate dalfampridine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(MS) (Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): Remainder of contract year
<b>Other Criteria</b>	(MS) (Reauth): Improvement in walking speed
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# APOKYN

## Products Affected

- APOKYN SUBCUTANEOUS SOLUTION  
CARTRIDGE
- *apomorphine hcl subcutaneous*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PD): Member not using medication with any 5-HT3 antagonist (e.g. ondansetron, granisetron, dolasetron, palonosetron, alosetron)
<b>Required Medical Information</b>	Parkinson??s Disease (PD): (1) Diagnosis of Parkinson??s disease, (2) Member is experiencing intermittent OFF Episodes, (3) Concomitant use of medication with other medications for the treatment of Parkinson??s disease (e.g. carbidopa/levodopa, pramipexole, ropinirole, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PD): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARMODAFINIL

## Products Affected

- *armodafinil*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NARCOLEPSY: (1) Diagnosis of Narcolepsy confirmed by a sleep study (unless prescriber provides justification that a sleep study is not feasible). OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). SHIFT WORK SLEEP DISORDER (SWSD): (1) One of the following: (a) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR (b) A sleep study demonstrating loss of a normal sleep-wake pattern (i.e., disturbed chronobiologic rhythmicity). (2) Documentation that the member has no other medical or mental disorder accounting for the symptoms.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy, SWSD, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AUSTEDO

## Products Affected

- AUSTEDO
- AUSTEDO XR
- AUSTEDO XR PATIENT TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Chorea-Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD)(Initial, Continuation): Prescribed by or in consultation with a neurologist or a psychiatrist.
<b>Coverage Duration</b>	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (CHD): Indefinite.
<b>Other Criteria</b>	(TD)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUVELITY

---

## Products Affected

- AUVELITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Major Depressive Disorder (MDD): (1) Diagnosis of major depressive disorder (MDD) (2) Inadequate response or inability to tolerate two formulary antidepressants indicated for MDD (e.g., bupropion, venlafaxine extended-release tablet or capsule, sertraline tablet, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(MDD): Approve if for continuation of therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BENLYSTA SC

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when the following are met: Systemic Lupus Erythematosus (SLE): (1) Diagnosis of active, autoantibody-positive SLE. (2) Member is receiving concurrent treatment with at least ONE of the following: steroids, antimalarials, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDS). Lupus Nephritis (LN): (1) Diagnosis of active lupus nephritis confirmed by kidney biopsy. (2) Member is receiving concurrent standard therapy (e.g. corticosteroids, immunosuppressants, azathioprine).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SLE): Prescribed by or in consultation with a rheumatologist. (LN): Prescribed by or in consultation with a nephrologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BESREMI

## Products Affected

- BESREMI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as ??off label?? with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BYLVAY

## Products Affected

- BYLVAY
- BYLVAY (PELLETS)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pruritus associated with progressive familial intrahepatic cholestasis (Pruritus with PFIC) (Initial): (1) Diagnosis of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), (2) Confirmed molecular diagnosis of PFIC type 1, 2, or 3, (3) Prescribed dose is consistent with FDA-approved package labeling and does not exceed a total daily dose of 6mg Cholestatic Pruritus with Alagille Syndrome (CPALGS) (Initial): (1) Diagnosis of Alagille Syndrome. (2) Molecular genetic testing confirms mutations in the JAG1 or NOTCH2 gene (3) Member is experiencing both of the following: (a) moderate to severe cholestatic pruritus (b) member has a serum bile acid concentrations above the upper limit of the normal reference for the reporting laboratory (4) An inadequate response or inability to tolerate at least two of the following treatments used for the relief of pruritus: (a) Ursodeoxycholic acid (e.g., Ursodiol) (b) Antihistamines (e.g., diphenhydramine, hydroxyzine) (c) Rifampin (d) Bile acid sequestrants (e.g., Questran, Colestid, Welchol).
<b>Age Restrictions</b>	(Pruritus with PFIC) (Initial, Reauth): Member is 3 months of age or older (CPALGS)(Initial, Reauth): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(Pruritus with PFIC)(CPALGS)(Initial, Reauth): Prescribed by or in consultation with a hepatologist or gastroenterologist
<b>Coverage Duration</b>	(All)(Initial):6 months (Pruritus w/PFIC)(Reauth):Indefinite (CPALGS)(Reauth):End of contract year
<b>Other Criteria</b>	(Pruritus with PFIC) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. improvement in pruritus symptoms), (2) Prescribed dose is consistent with FDA-approved package labeling and does not exceed a total daily dose of 6mg. (CPALGS) (Reauth): Positive clinical response to therapy (e.g., reduced bile acids, reduction in pruritis symptoms or ItchRO pruritis score).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

# CAMZYOS

## Products Affected

- CAMZYOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Obstructive hypertrophic cardiomyopathy (HCM) (1) Diagnosis of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). (2) Member's baseline left ventricular ejection fraction (LVEF) is greater than or equal to 55%. (3) Documentation of Valsalva left ventricular outflow tract (LVOT) gradient assessment at baseline. (4) Inadequate response or inability to tolerate one of the following: (a) one non-vasodilating beta-blocker (e.g., bisoprolol, propranolol), (b) one calcium-channel blocker (e.g., diltiazem, verapamil)
<b>Age Restrictions</b>	(HCM) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(HCM) (Initial, Reauth): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): 12 months
<b>Other Criteria</b>	(HCM) (Reauth): (1) Documentation of improvement in functional capacity and symptoms. (2) Member's left ventricular ejection fraction (LVEF) is greater than or equal to 50%. (3) Member does not have worsening heart failure symptoms.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CAPLYTA

## Products Affected

- CAPLYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate two generic antipsychotic products (e.g. aripiprazole, olanzapine, quetiapine, paliperidone). Bipolar Depression (BD): (1) Diagnosis of bipolar depression (2) Medication will be used as monotherapy or as adjunctive therapy with lithium or valproate (3) Inadequate response or inability to tolerate two medications indicated for bipolar depression (e.g. fluoxetine, Latuda, quetiapine, olanzapine)
<b>Age Restrictions</b>	(Schizophrenia, BP): member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Schizophrenia, BP): Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# CARBAGLU

## Products Affected

- *carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hyperammonemia Type III (HTIII): (1) Hyperammonemia due to the deficiency of the hepatic enzyme N-acetyl glutamate synthase (NAGS). Acute Hyperammonemia due to Propionic Acidemia or Methylmalonic Acidemia (AH): (1) Hyperammonemia due to propionic acidemia or methylmalonic acidemia.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CAYSTON

## Products Affected

- CAYSTON

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of CF. (2) Evidence of Pseudomonas Aeruginosa in the lungs. (3) Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam. (4) FEV1 between 25% and 75% of predicted
<b>Age Restrictions</b>	(CF): Member is 7 years of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with a pulmonologist OR infectious disease specialist or Specialist affiliated with a CF care center.
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CERDELGA

---

## Products Affected

- CERDELGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(GD): Member is CYP2D6 Ultra Rapid Metabolizer (URM)
<b>Required Medical Information</b>	Gaucher disease (GD): (1) Diagnosis of Type 1 Gaucher disease and member is CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) as detected by an FDA-cleared test for determining CYP2D6 genotype.
<b>Age Restrictions</b>	(GD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CHOLBAM

## Products Affected

- CHOLBAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(BASD, PD)(Initial, Reauth): Deny if there is documentation of extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorders
<b>Required Medical Information</b>	Bile Acid Synthesis Disorder (BASD) (initial): (1) Diagnosis of bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorder (PD) (initial): (1) Diagnosis of peroxisomal disorder. (2) Used as adjunctive treatment. (3) Member exhibits manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(BASD, PD): Hepatologist, Gastroenterologist, Medical geneticist, other specialist that treats inborn errors of metabolism
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): Indefinite
<b>Other Criteria</b>	(BASD,PD) (Reauth): Documentation of improved liver function tests from the start of treatment.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CIALIS

---

## Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(BPH): Concurrent use of nitrates.
<b>Required Medical Information</b>	Benign prostatic hyperplasia (BPH): (1) Diagnosis of BPH. (2) Inadequate response or inability to tolerate an alpha blocker (e.g. tamsulosin, terazosin) or a 5-alpha reductase inhibitor (e.g. dutasteride, finasteride).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CIBINQO

## Products Affected

- CIBINQO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AD): Concurrent use with any other biologic immunomodulator, Janus Kinase (JAK) inhibitors, or other immunosuppressants (e.g., azathioprine, cyclosporine)
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of refractory, moderate to severe AD (2) Inadequate response or inability to tolerate one systemic drug product, including biologics (e.g., Dupixent, methylprednisolone, prednisone) or documentation that a trial may be inappropriate.
<b>Age Restrictions</b>	(AD): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CIMZIA

## Products Affected

- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG
- CIMZIA SUBCUTANEOUS PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AS, PsA, PsO, RA, CD, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate two of the following: (a) secukinumab (Cosentyx), (b) adalimumab (Humira), (c) etanercept (Enbrel), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) upadacitinib (Rinvoq), (f) adalimumab-adbm (Cyltezo), (g) adalimumab-aaty (Yuflyma) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Humira, (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq, (e) Skyrizi, (f) Cosentyx, (g) Stelara, (h) Orencia, (i) Otezla, (j) Cyltezo, (k) Yuflyma OR documentation demonstrating that a trial may be inappropriate. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Humira, (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Stelara, (f) Otezla, (g) Cyltezo, (h) Yuflyma OR documentation demonstrating that a trial may be inappropriate. Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Humira, (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia, (f) Cyltezo, (g) Yuflyma OR documentation demonstrating that a trial may be inappropriate. Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate two of the following: (a) adalimumab (Humira), (b) ustekinumab (Stelara), (c) risankizumab (Skyrizi), (d) adalimumab-adbm (Cyltezo), (e) adalimumab-aaty (Yuflyma), (f) upadacitinib (Rinvoq) or documentation demonstrating that a trial may be inappropriate. Non-radiographic axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate one of the following: (a) two NSAIDs (b) Cosentyx (c) Rinvoq or (d) documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(AS, PsA, PsO, RA, CD, nr-axSpA): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CD): Prescribed by or in consultation with a gastroenterologist. (RA, AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist. (PsA, PsO): prescribed by or in consultation with a dermatologist or rheumatologist.

PA Criteria	Criteria Details
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# CINRYZE

---

## Products Affected

- CINRYZE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when: Hereditary Angioedema (HAE): (1) Diagnosis of hereditary angioedema (HAE) (2) For prophylaxis against HAE attacks.
<b>Age Restrictions</b>	(HAE): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# COMBINATION NSAID PRODUCTS

## Products Affected

- *ibuprofen-famotidine*
- *naproxen-esomeprazole mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(All Indications)(Initial): An inadequate response or inability to tolerate a two-week trial of BOTH of the following: (1) Concurrent administration of each of the components of the requested product, and (2) At least ONE generic alternative (when available) of each of the individual components of the requested product.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(All Indication) (Initial, Reauth): 1 year
<b>Other Criteria</b>	(All Indications)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CORLANOR

## Products Affected

- CORLANOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic Heart Failure (CHF): (1)Diagnosis of chronic heart failure. (2) stable, symptomatic chronic heart failure (3) left ventricular ejection fraction less than or equal to 35% and (4) sinus rhythm with resting heart rate greater than or equal to 70 beats per minute. (5) Member is clinically stable for at least 4 weeks on an optimized regimen which includes: (a) maximally tolerated doses of beta blockers or inability to tolerate beta blockers, (b) ACE inhibitors or ARBs or inability to tolerate ACE inhibitor or ARB. Chronic Heart Failure due to Dilated Cardiomyopathy in pediatric patients ages 6 months and older (CHF-DC): (1) Diagnosis of chronic heart failure due to dilated cardiomyopathy (2) Member is in sinus rhythm with an elevated heart rate.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHF, CHF-DC): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# COSENTYX

## Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsA, PsO, AS, nr-axSpA, ERA, HS): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD:(e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe plaque psoriasis. Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA, (2) Inadequate response or inability to tolerate two NSAIDs. Active Enthesitis-related Arthritis (ERA): (1) Diagnosis of active enthesitis-related arthritis (ERA), (2) Inadequate response or inability to tolerate methotrexate, (3) Inadequate response or inability to tolerate at least one NSAID (e.g. ibuprofen, naproxen, meloxicam, celecoxib). Hidradenitis Suppurativa (HS): (1) Diagnosis of HS.
<b>Age Restrictions</b>	(AS, nr-axSpA, HS): Member is 18 years of age or older. (PsO): Member is 6 years of age or older (PsA): Member is 2 years of age or older. (ERA): Member is 4 years of age or older.
<b>Prescriber Restrictions</b>	(PsO, HS): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AS, nr-axSpA, ERA): Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CRESEMBA [ORAL]

## Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Invasive Aspergillosis (IA): (1) For use in the treatment of invasive aspergillosis after inadequate response or inability to tolerate Voriconazole (oral Vfend). Mucormycosis (MC): (1) Diagnosis of invasive mucormycosis
<b>Age Restrictions</b>	(IA, MC): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(All Indications): Prescribed by or in consultation with an infectious disease specialist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CYSTEAMINE PRODUCTS

---

## Products Affected

- CYSTADROPS
- CYSTARAN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystinosis: (1) Diagnosis of cystinosis, (2) Member has corneal cystine crystal accumulation
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DAYBUE

## Products Affected

- DAYBUE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Rett syndrome (RS)(Initial): (1) Diagnosis of Rett syndrome (2) One of the following: (a) Presence of all of the following clinical signs and symptoms: (i) a pattern of development, regression, then recovery or stabilization (ii) partial or complete loss of purposeful hand skills such as grasping with fingers, reaching for things, or touching things on purpose (iii) partial or complete loss of spoken language (iv) repetitive hand movements, such as wringing the hands, washing, squeezing, clapping, or rubbing (v) gait abnormalities, including walking on toes or with an unsteady, wide-based, stiff-legged gait (b) Molecular genetic testing confirms mutations in the MECP2 gene
<b>Age Restrictions</b>	(RS)(Initial)(Reauth): member is 2 years of age or older
<b>Prescriber Restrictions</b>	(RS)(Initial)(Reauth): Prescribed by or in consultation with one of the following specialists: geneticist, pediatrician, neurologist
<b>Coverage Duration</b>	(Initial)(Reauth): 12 months
<b>Other Criteria</b>	(RS)(Reauth): (1) Documentation of positive clinical response to therapy as evidenced by an improvement in clinical signs and symptoms from baseline (e.g., hand behavior, walking/standing, speech, quality of life)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DAYVIGO

---

## Products Affected

- DAYVIGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Insomnia: (1) Diagnosis of insomnia. (2) Inadequate response or inability to tolerate generic ramelteon (Rozerem).
Age Restrictions	(Insomnia): Apply if member is greater than or equal to 65 years
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# DEFERASIROX

## Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*
- *deferasirox oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(NTDT, CIO-BT)(Initial, Continuation): CrCl less than 40 mL/min or serum creatinine more than 2 times the age-appropriate ULN, platelet counts less than 50,000/mcL
<b>Required Medical Information</b>	Chronic Iron Overload in nontransfusion-dependent thalassemia (NTDT) (Initial): (1) Diagnosis of Chronic iron overload in nontransfusion-dependent thalassemia syndromes,(2) liver iron concentration (LIC) of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dw), (3) serum ferritin greater than 300 mcg/L. (4) Serum ferritin levels consistently greater than 300 mcg/L (as demonstrated with at least two lab values within the previous two months). Chronic Iron Overload Caused by Blood Transfusions (CIO-BT)(Initial): (1) Diagnosis of chronic iron overload caused by blood transfusions (transfusional hemosiderosis). (2) Serum ferritin levels consistently greater than 1,000 mcg/L (as demonstrated with at least two lab values within the previous two months).
<b>Age Restrictions</b>	(NTDT)(Initial, Continuation): Member is 10 years of age or older. (CIO-BT) (Initial, Continuation): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial):3 months. (Continuation): 6 months
<b>Other Criteria</b>	(CIO-BT)(Continuation): (1) Decreased serum ferritin level compared with the baseline level for transfusion- dependent anemia. (NTDT)(Continuation): (1) Decreased serum ferritin level compared with the baseline level or reduction in LIC (liver iron concentration).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DIACOMIT

---

## Products Affected

- DIACOMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet syndrome (DS): (1) Diagnosis of seizures associated with Dravet syndrome (DS), (2) Used in combination with clobazam.
<b>Age Restrictions</b>	Member is 6 months of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DOJOLVI

---

## Products Affected

- DOJOLVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD): (1) Diagnosis of molecularly confirmed LC-FAOD, (2) Will be used as a source of calories and fatty acids.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# DOPTELET

## Products Affected

- DOPTELET ORAL TABLET 20 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic Liver Disease (CLD): (1) Baseline platelet count less than 50,000/mcL. Member is scheduled to undergo a procedure. Chronic Immune Thrombocytopenia (ITP)(Initial): (1) Baseline platelet count less than 30,000/mcL. (2) Inadequate response or inability to tolerate one of the following: (a) corticosteroids (b) immunoglobulins (c) splenectomy (d) Rituxan (rituximab)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ITP)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist
<b>Coverage Duration</b>	(CLD): 1 month. (ITP): 12 months
<b>Other Criteria</b>	(ITP)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	Yes

# DUPIXENT

## Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR MG/2ML
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Atopic Dermatitis (AD): (1) Diagnosis of moderate-severe atopic dermatitis. (2) inadequate response or inability to tolerate ONE of the following: (a) one topical steroid (medium potency or higher), (b) topical tacrolimus, (c) topical pimecrolimus, (d) topical eucrisa (crisaborole). Asthma (Initial): (1) ONE of the following: (a) Member has oral corticosteroid-dependent asthma or (b) Member has blood eosinophil levels of at least 150 cells/mcL at baseline or at least 300 cells/mcL within the past 12 months, (2) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication. Chronic Rhinosinusitis with Nasal Polyposis(CRSwNP)(Initial): (1) Diagnosis of chronic rhinosinusitis with nasal polyposis, (2) concurrent use of intranasal corticosteroid. Eosinophilic esophagitis (EoE)(Initial): (1) Diagnosis of eosinophilic esophagitis (EoE) (2) Member has symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, gastroesophageal reflux disease [GERD]/heartburn symptoms, chest pain, abdominal pain (3) Member has at least 15 intraepithelial eosinophils per high power (HPF) (4) Other causes of esophageal eosinophilia have been excluded (5) Member weighs at least 40 kg (6) Inadequate response or inability to tolerate at least an 8-week trial of one of the following: (a) proton pump inhibitors (e.g., pantoprazole, omeprazole (b) Topical (esophageal) corticosteroids (e.g., budesonide, fluticasone). Prurigo Nodularis (PN)(Initial): (1) Diagnosis of Prurigo Nodularis (PN) (2) inadequate response or inability to tolerate one medium or higher potency topical corticosteroid.</p>
<b>Age Restrictions</b>	<p>(Asthma)(Initial, Reauth): Member is 6 years old or older. (AD): Member is 6 months of age or older. (CRSwNP)(PN)(Initial, Reauth): Member is 18 years of age or older (EoE)(Initial, Reauth): Member is 12 years of age or older</p>

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(AD): Prescribed by/in consultation with a dermatologist, allergist, immunologist (Asthma)(Initial, Reauth): Prescribed by/in consultation with an allergist, immunologist or pulmonologist (CRSwNP)(Initial, Reauth): Prescribed by/in consultation with an allergist, immunologist or ENT specialist (EoE)(Initial, Reauth): Prescribed by/in consultation with gastroenterologist, allergist, or immunologist (PN)(Initial, Reauth): Prescribed by/in consultation with allergists/immunologist or dermatologist
<b>Coverage Duration</b>	(AD): Indefinite (Asthma, CRSwNP, EoE, PN) (Initial): 12 months (Reauth): 12 months
<b>Other Criteria</b>	(Asthma)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction in exacerbations, improvement in forced expiratory volume in 1 second [FEV1], decreased use of rescue medications) (2) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication. (CRSwNP) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction of nasal polyps score [NPS: 0-8 scale], improvement in nasal congestion/obstruction score [NC: 0-3 scale]), (2) Used in combination with another agent for CRSwNP. (EoE)(Reauth): (1) Documentation of a positive clinical response to therapy as evidenced by improvement of at least one of the following from baseline: (a)Symptoms (e.g., dysphagia, food impaction, heartburn, chest pain), (b) Histologic measures (e.g., esophageal intraepithelial eosinophil count), (c) Endoscopic measures (e.g., edema, furrows, exudates, rings, strictures). (PN)(Reauth): (1) Documentation of a positive clinical response to therapy (e.g., reduction in the number of nodular lesions from baseline, or improvement in symptoms from baseline)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EMGALITY

## Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Documentation of concomitant use with another injectable CGRP inhibitor.
<b>Required Medical Information</b>	Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine. OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine. Episodic Cluster Headaches (ECH) (Initial): (1) Diagnosis of episodic cluster headache, (2) Member has experienced at least 2 cluster periods lasting 6 days to 365 days, separated by pain-free periods lasting at least three months
<b>Age Restrictions</b>	(Migraine, ECH)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(Migraine, ECH)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, pain specialist
<b>Coverage Duration</b>	(Migraine, ECH)(Initial): 6 months, (Migraine, ECH)(Reauth):12 months
<b>Other Criteria</b>	(Migraine)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity). (ECH)(REAUTH): (1) Response to therapy as defined by a reduction in weekly cluster headache attacks.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No



# EMSAM

---

## Products Affected

- EMSAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Major depressive disorder (MDD): (1) Diagnosis of major depressive disorder. (2) Inadequate response or inability to tolerate ONE SSRI or SNRI. (3) 4-5 half-lives (approximately 1 week) has elapsed after discontinuation of antidepressants without long half-lives OR at least 5 weeks has elapsed after discontinuation with antidepressants with long half-lives (e.g. fluoxetine).
<b>Age Restrictions</b>	(MDD): Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENBREL

## Products Affected

- ENBREL MINI SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML • ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, PJIA, PsO, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine). Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine). Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of moderate to severe PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO. Ankylosing Spondylitis (AS): (1) Diagnosis of AS, (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate.
<b>Age Restrictions</b>	(PJIA, PsA): Member is 2 years of age or older. (RA, AS): Member is 18 years of age or older. (PsO): Member is 4 years of age or older
<b>Prescriber Restrictions</b>	(RA, PJIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (PsO): Prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENDARI

## Products Affected

- ENDARI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Sickle Cell Disease (SC)(Initial): (1) One of the following: (A) Member is using Endari with concurrent hydroxyurea therapy, OR (B) Member has an inadequate response or inability to tolerate hydroxyurea. (2) Member has had 2 or more painful sickle cell crises within the past 12 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SC)(Initial, Reauth): Prescribed by or in consultation with a hematologist or oncologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(Reauth): Documentation of positive clinical response to therapy (e.g. reduction in the number of sickle cell crises)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENSPRYNG

---

## Products Affected

- ENSPRYNG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Neuromyelitis Optica Spectrum Disorder (NMOSD)(Initial): (1) Diagnosis of NMSOD, (2) Member is anti-aquaporin-4 (AQP4) antibody positive.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(NMOSD)(Initial, Reauth): Prescribed by or in consultation with a neurologist or ophthalmologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(NMOSD)(Reauth): Positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENTYVIO SQ 2024

## Products Affected

- ENTYVIO SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(UC): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g., tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ulcerative Colitis (UC): (1) Diagnosis of moderately to severely active Ulcerative Colitis (2) Inadequate response or inability to tolerate two of the following: (a) adalimumab (Humira), (b) ustekinumab (Stelara), (c) upadacitinib (Rinvoq), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) adalimumab-adbm (Cyltezo), (f) adalimumab-aaty (Yuflyma) OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(UC): Prescribed by or in consultation with a gastroenterologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EPIDIOLEX

## Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet Syndrome (DS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. Lennox-Gastaut Syndrome (LGS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid, or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. Tuberous Sclerosis Complex (TSC): (1) Concurrent use with additional anti-epileptic(s). (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy
<b>Age Restrictions</b>	(DS, LGS, TCS): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(DS, LGS, TCS): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ESBRIET

---

## Products Affected

- ESBRIET
- *pirfenidone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(IPF): Prescribed by or in consultation a pulmonologist or lung transplant specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(REAUTH) (IPF): BOTH of the following (1) stabilization from baseline AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EUCRISA

---

## Products Affected

- EUCRISA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Inadequate response or inability to tolerate at least ONE of the following: (a) topical tacrolimus OR topical pimecrolimus , OR (b) generic, prescription medium potency or higher topical steroid.
<b>Age Restrictions</b>	(AD): Member is 3 months of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# EVEKEO

---

## Products Affected

- *amphetamine sulfate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Attention Deficit Hyperactivity Disorder (ADHD): (1) Diagnosis of ADHD. (2) Inadequate response or inability to tolerate TWO generic stimulant products (e.g. amphetamine/dextroamphetamine, methylphenidate) Narcolepsy: (1) Diagnosis of narcolepsy.
Age Restrictions	(ADHD): Member is 3 years of age or older. (Narcolepsy): Member is 6 years of age or older.
Prescriber Restrictions	
Coverage Duration	Remainder of Contract Year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# EVRYSDI

## Products Affected

- EVRYSDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Spinal Muscular Atrophy (SMA)(Initial): (1) Diagnosis of SMA, (2) Member has confirmed mutations in chromosome 5q that leads to SMN protein deficiency.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SMA)(Initial, Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial)(Reauth): 12 months
<b>Other Criteria</b>	(SMA)(Reauth): (1) Positive clinical response to therapy (e.g. improvement in ability to sit without support)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EXTENDED RELEASE METFORMIN

## Products Affected

- *metformin hcl er (mod) oral tablet extended release 24 hour 500 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(DM2)(Initial, Reauth): (1) Serum creatinine levels greater than or equal to 1.5 mg/dL in males, or serum creatinine levels greater than or equal to 1.4 mg/dL in females. (2) Hepatic impairment. (3) Metabolic acidosis, including diabetic ketoacidosis. (4) Used for preventing weight gain.
<b>Required Medical Information</b>	Diabetes Mellitus Type 2 (DM2)(Initial): (1) Diagnosis of DM2. (2) Member has a HgbA1C greater than 7.0%. All Indications: (1) Inadequate response or inability to tolerate both of the following: (a) Immediate release metformin, and (b) Extended-release metformin (generic Glucophage XR).
<b>Age Restrictions</b>	(DM2 for tablets) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): End of contract year.
<b>Other Criteria</b>	(DM2)(Reauth): Member has had a positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EYSUVIS

---

## Products Affected

- EYSUVIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Dry Eye Disease (DED)(Initial): (1) Diagnosis of DED
Age Restrictions	
Prescriber Restrictions	(DED)(Initial, Reauth): Prescribed by or in consultation with an ophthalmologist or optometrist.
Coverage Duration	(Initial, Reauth): 14 days
Other Criteria	(DED)(Reauth): (1) Positive clinical response to therapy (e.g. improvement in dry eye symptoms).
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# FASENRA

## Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when there is a documentation of the following: Severe Asthma (SA)(Initial): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by ONE of the following at initiation of therapy (a) blood eosinophil levels are at least 150 cells/microliter if dependent on daily oral corticosteroids or (b) blood eosinophil levels are at least 300 cells/microliter AND, (2) ONE of the following: (a) Member has had at least one asthma exacerbation requiring systemic corticosteroids within the past 12 months, or (b) Any prior intubation for asthma exacerbation, or (c) prior asthma-related hospitalization within the past 12 months, AND (3) Member is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: (a) high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g. leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR (b) one maximally-dosed combination ICS/LABA product).
<b>Age Restrictions</b>	(SA)(Initial): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(SA)(Initial): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist
<b>Coverage Duration</b>	(Initial): 12 months (Reauth): 12 months
<b>Other Criteria</b>	Subject to Part B vs Part D review (SA) (Reauth): (1) Member is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: (a) high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g. leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR (b) one maximally-dosed combination ICS/LABA product). (2) Positive clinical response to therapy (e.g. reduction in exacerbations, decreased use of rescue medications)

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FENTANYL CITRATE LOZENGE

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following: (1) pain associated with cancer, (2) long-acting pain medication regimen AND (3) member is opioid tolerant (e.g. at least one week where total daily dose is at least one of the following: 25mcg of transdermal fentanyl hourly, 30mg of oxycodone daily, 60mg of oral morphine daily, 8mg of oral hydromorphone daily, 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist.
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FERRIPROX

## Products Affected

- *deferiprone*
- FERRIPROX ORAL SOLUTION
- FERRIPROX TWICE-A-DAY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Transfusional Iron Overload (TIO): (1) Diagnosis of transfusional iron overload due to one of the following: (a) Thalassemia syndromes, (b) sickle cell disease, (c) other transfusion-dependent anemias. (2) Inadequate response or inability to tolerate current chelation therapy.
<b>Age Restrictions</b>	(TIO): Member is 3 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# FILSPARI

## Products Affected

- FILSPARI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Immunoglobulin A nephropathy (IgAN)(Initial): (1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) as confirmed by a kidney biopsy (2) Member is at risk of rapid disease progression [e.g., generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g, or by other criteria such as clinical risk scoring using the International IgAN Prediction Tool] (3) Used to reduce proteinuria (4) Member has an estimated glomerular filtration rate (eGFR) of greater than or equal to 30 mL/min/1.75 m <sup>2</sup> (5) Member has had an inadequate response or inability to tolerate at minimum 90-day trial of a maximally tolerated dose of one of the following (a) Angiotensin-receptor blockers (ARB) (e.g., losartan, valsartan), (b) Angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril) (6) Medication will not be used in combination with any of the following (a) Angiotensin receptor blockers, (b) Endothelin receptor antagonists (ERAs) (e.g., ambrisentan, bosentan, Opsumit), (c) Aliskiren
<b>Age Restrictions</b>	(IgAN)(Initial)(Continuation): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(IgAN)(Initial)(Continuation): Prescribed by or in consultation with a nephrologist
<b>Coverage Duration</b>	(Initial)(Continuation): 12 months
<b>Other Criteria</b>	(IgAN)(Continuation): (1) Documentation of positive clinical response to therapy from baseline as demonstrated by a decrease in urine protein-to-creatinine ration (UPCR).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FINTEPLA

## Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet Syndrome (DS): Inadequate response or inability to tolerate ONE of the following: (a) clobazam, (b) valproic acid, (c) divalproex sodium, (d) topiramate. Lennox-Gastaut Syndrome (LGS): (1) Diagnosis of seizures associated with Lennox-Gastaut Syndrome (LGS) (2) Inadequate response or inability to tolerate ONE of the following: valproic acid, lamotrigine, topiramate, felbamate, clobazam.
<b>Age Restrictions</b>	(DS, LGS): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	(DS, LGS): Prescribed by or in consultation with a neurologist.
<b>Coverage Duration</b>	Indefinite.
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FIRDAPSE

---

## Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(LEMS)(Initial, Continuation): history of seizures
<b>Required Medical Information</b>	Lambert-Eaton Myasthenic Syndrome (LEMS)(Initial): (1) Diagnosis of LEMS. (2) Neurological symptoms persist after treatment of malignancy, when malignancy is present.
<b>Age Restrictions</b>	(LEMS)(Initial, Continuation): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(LEMS)(Initial, Continuation): Prescribed by or in consultation with a neurologist.
<b>Coverage Duration</b>	(Initial):90 Days, (Continuation): Indefinite
<b>Other Criteria</b>	(LEMS)(CONTINUATION): positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GATTEX

---

## Products Affected

- GATTEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Short Bowel Syndrome (SBS)(Initial): (1) Diagnosis of Short Bowel Syndrome, (2) individual receives parenteral support at least three times per week for at least 12 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SBS): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	(Initial, Reauth): 6 months
<b>Other Criteria</b>	(SBS)(REAUTH): (1)Reduction in parenteral support from baseline (prior to initiation of Gattex therapy)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GROWTH HORMONES

## Products Affected

- GENOTROPIN MINIQUICK SUBCUTANEOUS PREFILLED SYRINGE 0.4 MG, 0.6 MG, 0.8 MG, 1 MG, 1.2 MG, 1.4 MG, 1.6 MG, 1.8 MG, 2 MG
- GENOTROPIN SUBCUTANEOUS CARTRIDGE 5 MG
- NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN-INJECTOR
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) Growth Failure in Children (GFC)(Initial): (A) Diagnosis of growth hormone deficiency confirmed by one of the following: (I) Height is documented by one of the following (utilizing age and gender growth charts related to height): (a) Height is greater than 2.0 standard deviations [SD] below midparental height (b) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) (II) Growth velocity is greater than 2 SD below mean for age and gender (III) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (eg, delayed is greater than 2 years compared with chronological age), (B) documentation of bone age, (C) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine. (2) Small for Gestational Age (SGA)(Initial): (A) Diagnosis of SGA, (B) Clinical documentation of no catch-up growth by 2 to 4 years of age. (3) Growth Failure Associated with Chronic Kidney Disease (GF-CKD) (Initial), (4) Growth failure associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or short stature homeobox-containing gene (SHOX) deficiency (Initial), (5) Diagnostically confirmed Growth Hormone Deficiency in adults (GHDA)(Initial), OR (6) Idiopathic Short Stature (ISS)(Initial): (A) Diagnosis of ISS defined by height standard deviation score (SDS) less than or equal to 2.25, (B) Documentation of growth velocity less than 25th percentile for bone age.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(All Other Indications)(Initial): Prescribed by or in consultation with an endocrinologist. (GF-CKD)(Initial) : Prescribed by or in consultation with an endocrinologist or nephrologist
<b>Coverage Duration</b>	(Initial, Continuation): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	(GHDA)(Continuation): Annual clinical re-evaluation by the treating endocrinologist. (GFC)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist, (2) Growth velocity greater than or equal to 2.5cm/year. (SGA, ISS)(Continuation): (1) Increase in growth velocity from baseline, (2) Annual clinical re-evaluation by the treating endocrinologist. (GF-CKD)(Continuation): (1) No history of renal transplant, (2) Annual clinical re-evaluation by the treating endocrinologist. (Growth Failure Associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or Short Stature Homeobox-Containing Gene (SHOX) Deficiency)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HAEGARDA

---

## Products Affected

- HAEGARDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hereditary Angioedema (HAE): (1) Diagnosis of hereditary angioedema (HAE), (2) For prophylaxis against HAE attacks.
<b>Age Restrictions</b>	(HAE): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HETLIOZ

## Products Affected

- HETLIOZ
- *tasimelteon*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Non-24 Hour Sleep-Wake Cycle (Non-24)(Initial): (1) Diagnosis of a circadian period greater than 24 hours (also known as non-24-hour sleep-wake disorder), (2) Member is totally blind (has no light perception). Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS)(Initial): (1) Diagnosis of SMS, (2) Member is experiencing nighttime sleep disturbances.
<b>Age Restrictions</b>	(SMS)(Initial): Member is 16 years of age or older
<b>Prescriber Restrictions</b>	(Non-24, SMS)(Initial, Reauth): Prescribed by or in consultation with a sleep specialist or neurologist.
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(Non-24)(Reauth): Documentation of positive clinical response (SMS)(Reauth): Documentation of positive clinical response to therapy (e.g. improvement in nighttime total sleep time, improvement in nighttime sleep quality)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HETLIOZ LQ

## Products Affected

- HETLIOZ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)(Initial): (1) Diagnosis of SMS, (2) Member is experiencing nighttime sleep disturbances
<b>Age Restrictions</b>	(SMS)(Initial): Member is 3 to 15 years of age
<b>Prescriber Restrictions</b>	(SMS)(Initial, Reauth): Prescribed by or in consultation with a sleep specialist or neurologist.
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(SMS)(Reauth): Documentation of positive clinical response to therapy (e.g. improvement in nighttime total sleep time, improvement in nighttime sleep quality)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HIGH DOSE OPIOIDS

## Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 62.5 mcg/hr, 87.5 mcg/hr*
- *fentanyl transdermal patch 72 hour 50 mcg/hr, 75 mcg/hr*
- *hydromorphone hcl er oral tablet extended release 24 hour*
- *hydromorphone hcl oral tablet 4 mg, 8 mg*
- *methadone hcl oral solution*
- *methadone hcl oral tablet*
- *morphine sulfate er beads oral capsule extended release 24 hour 120 mg*
- *morphine sulfate er oral capsule extended release 24 hour 100 mg, 60 mg, 80 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg, 60 mg*
- *oxycodone hcl oral tablet 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 20 mg, 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 40 mg*
- *XTAMPZA ER*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NEW TO HIGH DOSE OPIOID THERAPY : ONE of the following (A) pain associated with cancer, (B) chronic non-cancer pain and BOTH of the following (1) member is opioid tolerant (e.g. at least one week where total daily dose is at least one of the following: 30mg of oxycodone, 60mg of oral morphine, 8mg of oral hydromorphone, 25mg of oral oxymorphone or an equianalgesic dose of another opioid) AND (2) the member has been evaluated for non-opioid prescription pharmacologic treatment prior to initiation of high dose opioid therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable. CONTINUING HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (1) pain associated with cancer OR (2) chronic non-cancer pain and ALL (a) member's pain has been assessed within the last 6 months AND (b) member has clinically meaningful improvement in pain and functioning that outweighs risks to patient safety AND (c) member is not being treated for substance abuse
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# HRM

## Products Affected

- *butalbital-acetaminophen oral tablet 50-325 mg*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-aspirin-caffeine oral capsule*
- *chlordiazepoxide-clidinium*
- *clemastine fumarate oral syrup*
- *dipyridamole oral*
- LIBRAX
- *metaxalone*
- *promethazine hcl oral syrup*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal suppository 12.5 mg, 25 mg*
- PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM ESTROGENS

## Products Affected

- AMABELZ ORAL TABLET 0.5-0.1 MG
- BIJUVA
- CLIMARA PRO
- COMBIPATCH
- DOTTI
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- FYAVOLV
- JINTELI
- LYLLANA
- MENOSTAR
- MIMVEY
- *norethindrone-eth estradiol*
- PREMARIN ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ONE of the following: (1) Inadequate response or inability to tolerate vaginal estrogen preparations (e.g. vaginal tablets, rings, or cream, etc.) OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM KETOROLAC

---

## Products Affected

- *ketorolac tromethamine oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ONE of the following: (1) Inadequate response or inability to tolerate TWO alternative NSAIDs such as meloxicam, naproxen, celecoxib, ibuprofen, etc. OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	One Month
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM NON BENZODIAZEPINE HYPNOTICS

## Products Affected

- *eszopiclone oral tablet 3 mg*
- *zolpidem tartrate er oral tablet extended release 12.5 mg*
- *zolpidem tartrate oral tablet 10 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	(Initial, Reauth): Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): 2 years
<b>Other Criteria</b>	(REAUTH): Prescriber is aware of the risk versus benefit of using the medication chronically (greater than 90 days)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM NORGESIC

## Products Affected

- NORGESIC
- *orphenadrine-aspirin-caffeine oral tablet 25-385-30 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) For age 65 and older: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly. (2) Inadequate response or inability to tolerate two generic skeletal muscle relaxants (e.g., tizanidine, chlorzoxazone 500mg, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HRM SHORT TERM SKELETAL MUSCLE RELAXANTS

## Products Affected

- *carisoprodol oral*
- *cyclobenzaprine hcl er oral capsule extended release 24 hour 15 mg*
- *cyclobenzaprine hcl oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Acute Muscle Spasms (AMS): Prescriber attestation that drug will be used only for short periods (up to 2 or 3 weeks). All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly.
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(AMS): 1 year. (All other indications): 2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HUMIRA

## Products Affected

- HUMIRA (2 PEN) PEN-INJECTOR KIT 80 MG/0.8ML
- HUMIRA (2 SYRINGE) SUBCUTANEOUS
  - HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA (2 SYRINGE) SUBCUTANEOUS
  - HUMIRA-PED>/=40KG CROHNS START
- HUMIRA (2 SYRINGE) SUBCUTANEOUS
  - HUMIRA-PED>/=40KG UC STARTER
- HUMIRA (2 SYRINGE) SUBCUTANEOUS
  - HUMIRA-PSORIASIS/UVEIT STARTER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, AS, JIA, PsA, PsO, CD, UC, HS, UV): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Juvenile Idiopathic Arthritis (JIA): (1) Diagnosis of moderate to severe JIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO.
<b>Age Restrictions</b>	(JIA, UV): Member is 2 years of age or older. (CD): Member is 6 years of age or older. (HS): Member is 12 years of age or older. (RA, AS, PsA, PsO): Member is 18 years of age or older. (UC): Member is 5 years of age or older.
<b>Prescriber Restrictions</b>	(RA, JIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (PsO, HS): Prescribed by or in consultation with a dermatologist. (CD, UC): Prescribed by or in consultation with a gastroenterologist. (UV): Prescribed by or in consultation with a rheumatologist or ophthalmologist.
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine). Ulcerative Colitis (UC): (1) Diagnosis of UC. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine). Hidradenitis Suppurativa (HS): (1) Diagnosis of HS. Uveitis (UV)(Initial): (1) Diagnosis of non-infectious intermediate, posterior, or pan-uveitis. (2) Inadequate response or inability to tolerate corticosteroids and at least one immunosuppressive drug (e.g. azathioprine, cyclosporine, methotrexate, mycophenolate).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INBRIJA

## Products Affected

- INBRIJA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PD): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INCRELEX

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(GHGD, PIGF-1D) (Initial and Continuation): Known or suspected malignancy, closed epiphyses, concurrent GH therapy
<b>Required Medical Information</b>	Growth Hormone Gene Deletion (GHGD): (Initial) (1) Diagnosis of growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. Severe Primary IGF-1 Deficiency (PIGF-1D): (Initial) (1) Diagnosis of Severe primary IGF-1 deficiency (2) height standard deviation score less than or equal to -3.0 (3) basal IGF-1 standard deviation score less than or equal to -3.0 AND normal or elevated growth hormone.
<b>Age Restrictions</b>	(GHGD, PIGF-1D) (Initial and Continuation): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(GHGD, PIGF-1D) (Initial and Continuation) Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	(Initial and continuation): 12 months
<b>Other Criteria</b>	(GHGD, PIGF-1D)(CONTINUATION): (1) Documentation of increase in growth velocity from baseline AND (2) Annual clinical re-evaluation by an endocrinologist AND (3) BOTH of the following: (a) Expected adult height is not obtained (b) documentation of expected adult height goal
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INGREZZA

## Products Affected

- INGREZZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD) (Initial): (1) Diagnosis of moderate to severe tardive dyskinesia (2) documentation of baseline AIMS and (3) one of the following: (a) persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication, or (b) member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(TD) (Initial, Reauth): Prescribed by or in consultation with a neurologist or +1125 a psychiatrist
<b>Coverage Duration</b>	(TD) (Initial): 3 months (TD)(Reauth): indefinite
<b>Other Criteria</b>	(TD) (Reauthorization): Valbenazine (Ingrezza) is reapproved with documentation of positive clinical response, as demonstrated by improvement in AIMS, to Ingrezza therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INJECTABLE METHOTREXATE

## Products Affected

- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of severe, active rheumatoid arthritis (RA), (2) Inadequate response or inability to tolerate oral methotrexate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate oral methotrexate. Polyarticular juvenile idiopathic arthritis (pJIA): (1) Diagnosis of pJIA, (2) Inadequate response or inability to tolerate oral methotrexate. Psoriasis: (1) Diagnosis of severe psoriasis, (2) Inadequate response to BOTH of the following: (a) oral methotrexate AND (b) topical steroids (e.g. clobetasol propionate cream/ointment, betamethasone cream/ointment, etc.).
<b>Age Restrictions</b>	(Psoriasis): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, pJIA): Recommended by rheumatologist. (PSA): Recommended by a rheumatologist or dermatologist. (Psoriasis): Recommended by dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INTRAVENOUS IMMUNE GLOBULINS (IVIG)

## Products Affected

- BIVIGAM INTRAVENOUS SOLUTION 5 GM/50ML GM/50ML
- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/200ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PANZYGA
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial): History of hypersensitivity (including anaphylaxis or severe systemic reaction) to immune globulin or any component of the preparation.
<b>Required Medical Information</b>	Part D is medically necessary when ONE of the following is present: (1) Autoimmune mucocutaneous blistering disease pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, benign mucous membrane pemphigoid, epidermolysis bullosa acquisita and ONE of the following: (a) inadequate response or inability to tolerate conventional therapy (i.e. steroids, immunosuppressants) OR (b) rapidly progressive disease in conjunction with conventional therapy (i.e. steroids, immunosuppressants). (2) Acute Idiopathic Thrombocytopenia Purpura (ITP) and ONE of the following (a) management of acute bleeding (b) used to increase platelet count prior to surgical procedures) (c) severe thrombocytopenia (platelets less than 20, 000 per uL) or (d) high risk for intracerebral hemorrhage. (3) Chronic ITP and ALL of the following (a) inadequate response or inability to tolerate corticosteroids (b) duration of illness greater than 6 months (c) platelets persistently less than 20,000/ uL. (4) Chronic B-cell lymphocytic leukemia with IgG less than 600mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy. (5) Hematopoietic stem cell transplant and IgG less than 400mg/dL. (6) HIV and all of the following (a) less than 14 years of age (b) evidence of qualitative or quantitative humoral immunologic defects and (c) current bacterial infection despite antimicrobial prophylaxis. (7) Solid organ transplant. (8) Chronic Inflammatory Demyelinating Polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids. (9) Dermatomyositis or Polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies), biopsy, EMG, or MRI) and inadequate response or inability to tolerate steroids or immunosuppressants. (10) Guillain Barre syndrome with impaired function (i.e. unable to stand or walk without aid).
<b>Age Restrictions</b>	



PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a physician who has specialized expertise in managing patients on immune globulin therapy (e.g. immunologist, hematologist, neurologist).
<b>Coverage Duration</b>	(All Indications): 6 months
<b>Other Criteria</b>	Subject to Part B vs Part D review. (11) Lambert Eaton myasthenic syndrome and an inadequate response or inability to tolerate steroids, immunosuppressants, or cholinesterase inhibitors (12) Multifocal motor neuropathy diagnosed by electrodiagnostic studies. (13) Acute exacerbations of multiple sclerosis (MS) unresponsive to steroids. (14) Myasthenia gravis and an inadequate response or inability to tolerate at least 8 weeks of standard therapy (e.g., corticosteroids, azathioprine, cyclosporine, cyclophosphamide, cholinesterase inhibitors) (15) Myasthenic crisis (16) Stiff person syndrome and an inadequate response or inability to tolerate standard therapy (e.g., muscle relaxants, benzodiazepines, and gabapentin-related medications) (17) Severe, active SLE and an inadequate response or inability to tolerate steroids (18) Kawasaki disease. (All Indications)(CONTINUATION): (1) Documentation of clinical improvement as appropriate to the diagnosis (e.g. clinical improvement in symptoms, Rankin score and Activities of Daily Living (ADL) scores, etc.)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ISTURISA

---

## Products Affected

- ISTURISA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cushing's disease (CD): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative (3) Member has inadequate response or inability to tolerate Signifor [LAR].
<b>Age Restrictions</b>	(CD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CD): Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# JUXTAPID

## Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(HoFH)(Initial, Reauth): Moderate-severe liver impairment, active liver disease, unexplained LFT abnormalities. Juxtapid: Pregnancy, concomitant use with strong or moderate CYP3A4 inhibitors.
<b>Required Medical Information</b>	Homozygous Familial Hypercholesterolemia (HoFH): (1) Diagnosis of HoFH with ONE of the following: (a) Genetic confirmation of 2 mutant alleles at the LDL receptor, Apo B, PCSK9, or ARH adaptor protein gene locus (b) Untreated LDL-C greater than 500 mg/dL or treated LDL cholesterol greater than or equal to 300 mg/dL or treated non-HDL cholesterol greater than or equal to 330 mg/dL together with either of the following: (i) Tendinous xanthoma prior to 10 years of age (ii) Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents AND (2) Inadequate response or inability to tolerate the combination of BOTH of the following: (a) Either ezetimibe or a Bile Acid Sequestrant (e.g. cholestyramine) AND (b) ONE of the following: (i) ONE high potency statin at the maximally tolerated dose (e.g. atorvastatin, rosuvastatin) OR (ii) Inability to tolerate statin therapy as determined by one of the following: (A) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (B) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (C) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (D) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (3) Inadequate response or inability to tolerate BOTH of the following: (a) Repatha and (b) Praluent.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HoFH)(Initial, Reauth): Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 6 months
<b>Other Criteria</b>	(HoFH)(REAUTH): (1) Documentation of reduction in LDL level since initiation of therapy

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# JYNARQUE

## Products Affected

- JYNARQUE ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Baseline serum transaminases and bilirubin prior to initiation of therapy
<b>Age Restrictions</b>	(Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(Initial and Reauth): Prescribed by or in consultation with a nephrologist or kidney transplant specialist
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): 12 months.
<b>Other Criteria</b>	(REAUTH): (1) ONE of the following (a) decline in kidney function has slowed or (b) kidney pain has improved and (2) serum transaminase less than 3 times the upper limit of normal and (3) bilirubin less than 2 times upper limit of normal
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KALYDECO

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis with documentation of one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data, (2) Mutation was documented by an FDA-cleared CF mutation test to detect the presence of the CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions.
<b>Age Restrictions</b>	(CF): Member is 1 month of age or older for granules. Member is 6 years of age or older for tablets
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with is a pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KERENDIA

## Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic kidney disease associated with type 2 diabetes (CKD with T2D): (1) Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D), (2) One of the following (a) Minimum 30-day trial of a maximally tolerated dose and member will continue therapy with ONE of the following (i) generic angiotensin-converting enzyme (ACE) inhibitor (e.g. benazepril, lisinopril), (ii) generic angiotensin II receptor blocker (ARB) (e.g. losartan, valsartan), (b) Member has contraindication or intolerance to ACE inhibitors or ARBs
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KEVZARA

## Products Affected

- KEVZARA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PMR): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Rinvog, (d) Xeljanz/Xeljanz XR, (e) Orencia, (f) adalimumab-adbm (Cyltezo), (g) adalimumab-aaty (Yuflyma) OR documentation demonstrating that a trial may be inappropriate. Polymyalgia Rheumatica (PMR): (1) Diagnosis of polymyalgia rheumatica (2) Inadequate response or inability to tolerate corticosteroids (e.g., prednisone)
<b>Age Restrictions</b>	(RA, PMR): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, PMR): Prescribed by or in consultation with a rheumatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# KINERET

## Products Affected

- KINERET SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, NOMID, DIRA): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orenzia, (f) adalimumab-adbm (Cyltezo), (g)adalimumab-aaty (Yuflyma) OR documentation demonstrating that a trial may be inappropriate. Neonatal-Onset Multisystem Inflammatory Disease (NOMID): (1) Diagnosis of NOMID. (2) Diagnosis has been confirmed by one of the following: (a) NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation (b) Evidence of active inflammation including both of the following: (i) clinical symptoms (e.g. rash, fever, arthralgia) (ii) elevated acute phase reactants (e.g. ESR, CRP). Deficiency of Interleukin-1 Receptor Antagonist (DIRA): (1) Diagnosis of DIRA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(RA, NOMID, DIRA): Prescribed by or in consultation with a rheumatologist or pediatric specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KORLYM

## Products Affected

- KORLYM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(HCS): Pregnancy
<b>Required Medical Information</b>	Hyperglycemia in members with Cushing Syndrome (HCS): (1) Hyperglycemia secondary to hypercortisolism in adult member with endogenous Cushing syndrome, (2) member has type 2 diabetes mellitus or glucose intolerance, (3) member has failed surgery or is not a candidate for surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HCS): Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LETAIRIS

## Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIDOCAINE TRANSDERMAL PATCH

## Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Post-Herpetic Neuralgia (PHN): (1) Diagnosis of post-herpetic neuralgia. (2) Inadequate response or inability to tolerate generic lidocaine 5% patch. Diabetic Peripheral Neuropathy (DPN): (1) Diagnosis of diabetic peripheral neuropathy. (2) Inadequate response or inability to tolerate generic lidocaine 5% patch
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIVMARLI

## Products Affected

- LIVMARLI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cholestatic Pruritus with Alagille Syndrome (CPALGS) (Initial): (1) Diagnosis of Cholestatic Pruritus with Alagille Syndrome. (2) Diagnosis of ALGS confirmed by one of the following: (A) liver histology showing bile duct scarcity, OR (B) THREE of the following clinical features (i) hepatic: cholestasis, jaundice, hepatomegaly (ii) Facial: high prominent forehead, pointed chin, deep-set eyes (iii) Ocular: posterior embryotoxon, optic disc drusen (iv) Cardiac: pulmonary stenosis, tetralogy of Fallot (v) Skeletal: butterfly vertebrae, pathological fractures (vi) Renal: renal dysplasia, renal tubular acidosis (vii) Vascular: intracranial bleeding, CNS/pulmonary vascular malformations, OR (C) genetic mutation in the JAG1 or NOTCH2 genes. (3) An inadequate response or inability to tolerate at least two of the following treatments used for the relief of pruritus: (a) Ursodeoxycholic acid (e.g. Ursodiol) (b) Antihistamines (e.g. diphenhydramine, hydroxyzine) (c) Rifampin (d) Bile acid sequestrants (e.g. Questran, Colestid, Welchol).
<b>Age Restrictions</b>	(CPALGS): Member is 3 months of age or older
<b>Prescriber Restrictions</b>	(CPALGS) (Initial, Reauth): Prescribed by or in consultation with a gastroenterologist or hepatologist.
<b>Coverage Duration</b>	(CPALGS)(Initial): 6 months (CPALGS)(Reauth): End of contract year
<b>Other Criteria</b>	(CPALGS) (Reauth): Positive clinical response to therapy (e.g. reduced bile acids, reduction in pruritus symptoms or ItchRO pruritis score).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIVTENCITY

## Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cytomegalovirus (CMV): (1) Diagnosis of cytomegalovirus (CMV) infection/disease, (2) Member is a recipient of one of the following (a) Hematopoietic stem cell transplant, (b) solid organ transplant, (3) Inadequate response to a minimum 2 weeks duration or inability to tolerate one of the following therapies at an appropriately indicated dose (a) intravenous (IV) ganciclovir, (b) oral valganciclovir, (c) intravenous (IV) foscarnet, (d) intravenous (IV) cidofovir, (4) Member weighs greater than or equal to 35kg
<b>Age Restrictions</b>	(CMV): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(CMV): Prescribed by or in consultation with a provider who specializes in one of the following areas (1) transplant, (2) infectious disease
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LUMRYZ

## Products Affected

- LUMRYZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CN, EDSN (Initial, Reauth): Concurrent use of sedative hypnotics and alcohol
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy, (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible and (3) Inadequate response or inability to modafinil or armodafinil.
<b>Age Restrictions</b>	(CN, EDSN)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CN, EDSN)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# METFORMIN IR

## Products Affected

- *metformin hcl oral tablet 625 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(DM) (Initial): (1) Diagnosis of Type 2 Diabetes Mellitus (DM2) (2) Inadequate response to at least a 12-week trial of generic metformin 500mg, metformin 850mg, or metformin 1000mg as evidenced by Hemoglobin A1C level above the member's goal, or inability to tolerate generic metformin 500mg, metformin 850mg, or metformin 1000mg.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(DM) (Reauth): (1) Member has experienced an objective response to therapy demonstrated by an improvement in HbA1c from baseline
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# MODAFINIL

## Products Affected

- *modafinil oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>NARCOLEPSY: (1) Diagnosis of Narcolepsy confirmed by a sleep study (unless prescriber provides justification that a sleep study is not feasible).</p> <p>OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). SHIFT WORK SLEEP DISORDER (SWSD): (1) One of the following: (a) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR (b) A sleep study demonstrating loss of a normal sleep-wake pattern (i.e., disturbed chronobiologic rhythmicity). (2) Documentation that the member has no other medical or mental disorder accounting for the symptoms. Multiple Sclerosis (MS) Related Fatigue: (1) Diagnosis of Multiple Sclerosis (MS) related fatigue, (2) Used in combination with standard educational therapies (e.g. psychoeducation, behavioral programs, scheduled naps, additional non-pharmacological therapies, etc.) (All Indications): Inadequate response or inability to tolerate generic modafinil (applies to Brand Provigil)</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy, SWSD, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MYALEPT

---

## Products Affected

- MYALEPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Generalized Lipodystrophy (GL): (1) Diagnosis of congenital or acquired generalized lipodystrophy.
Age Restrictions	
Prescriber Restrictions	(GL): Prescribed by or in consultation with an endocrinologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# MYCAPSSA

## Products Affected

- MYCAPSSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Acromegaly)(Initial): (1) One of the following: (a) Inadequate response to surgical resection and/or pituitary irradiation, (b) member is not a candidate for surgical resection or pituitary irradiation (2) Inadequate response or inability to tolerate a dopamine agonist (e.g. bromocriptine or cabergoline) at maximally tolerated doses (3) Member has responded to and tolerated treatment with octreotide or lanreotide.
<b>Age Restrictions</b>	(Acromegaly): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(Acromegaly) (Reauth): Positive clinical response to therapy (e.g. reduction or normalization of IGF-1/GH level for same age and sex)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MYFEMBREE

## Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Uterine Leiomyomas (UL)(Initial): (1) Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), (2) Member is premenopausal, (3) ONE of the following: (a) Inadequate response or inability to tolerate one of the following for no more than 30 days: combination (estrogen/progestin) contraceptive, progestins, tranexamic acid, OR (b) Member has had a previous interventional therapy to reduce bleeding (e.g. uterine-artery embolization and magnetic resonance-guided focused ultrasonography), (4) Treatment duration of therapy has not exceeded a total of 24 months.</p> <p>(Endometriosis)(Initial) (1) Diagnosis of moderate to severe pain associated with endometriosis (2) member is premenopausal (3) One of the following (a) Inadequate response or inability to tolerate one of the following for at least 3 months (danazol, combination (estrogen/progestin) contraceptive, progestins (b) member has had surgical ablation to prevent recurrence (4) Treatment duration of therapy has not exceeded a total of 24 months</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	<p>(UL) (Reauth): (1) Member has improvement in bleeding associated with uterine leiomyomas (fibroids) (e.g. significant/sustained reduction in menstrual blood loss per cycle, improved quality of life, etc.), (2) Treatment duration of therapy has not exceeded a total of 24 months.</p> <p>(Endometriosis)(Reauth) (1) Member has improvement in pain associated with endometriosis (e.g., improvement in dysmenorrhea and nonmenstrual pelvic pain) (2) Treatment duration of therapy has not exceeded a total of 24 months</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

# NEXLETOL/NEXLIZET

## Products Affected

- NEXLETOL
- NEXLIZET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Heterozygous Familial Hypercholesterolemia (HeFH) OR Atherosclerotic Cardiovascular Disease (ASCVD) (Initial): (1) One of the following: (A) Diagnosis of HeFH, OR (B) Diagnosis of ASCVD as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid). (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after at least 8 weeks of one low, moderate or high-intensity statin therapy and member will continue to receive statin therapy at maximally tolerated dose OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (3) One of the following: (A) Member has been receiving at least 8 weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy OR (B) Member has contraindication or intolerance to ezetimibe (Zetia).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months
<b>Other Criteria</b>	(HeFH, ASCVD) (Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) One of the following: (A) Member continues to receive other lipid-lowering therapy (e.g. statins, ezetimibe) at the maximally tolerated dose OR (B) Member has inability to tolerate other lipid-lowering therapy (e.g. statins, ezetimibe)
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# NON-ORAL ANTIBIOTICS

## Products Affected

- NUZYRA
- SIVEXTRO
- ZEMDRI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Part D is medically necessary when documentation of a current bacterial infection and an inadequate response or inability to tolerate at least TWO drugs to which the organism is susceptible OR the requested agent is the only antibiotic to which the organism is susceptible.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with an infectious disease specialist OR oncologist
<b>Coverage Duration</b>	(Initial, Reauth): 1 month
<b>Other Criteria</b>	Subject to Part B vs Part D review. Subject to additional clinical review for ESRD-related use - if applicable. (REAUTH): Prescriber attests that an infectious disease consult determines that a longer duration of therapy is required.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



## NON-PREFERRED HEPATITIS C AGENTS

### Products Affected

- SOVALDI ORAL PACKET
- SOVALDI ORAL TABLET 200 MG
- VOSEVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) Documentation of member's Hepatitis C genotype. (2) Prescribed regimen is consistent with the current AASLD/ IDSA guidance. (3) Inability to tolerate ONE of the following when appropriate per the current AASLD/IDSA guidance: Harvoni, Epclusa, or Mavyret.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Duration will be applied consistent with AASLD/ IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NOURIANZ

---

## Products Affected

- NOURIANZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PD): Prescribed by or in consultation with a neurologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NOXAFIL

## Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Treatment of invasive aspergillosis (TAI): Diagnosis of TAI. Prophylaxis of Invasive Aspergillus Infections (AI): (1) For use in prophylaxis of invasive Aspergillus infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend). Prophylaxis of Invasive Candida Infections(CI): (1) For use in prophylaxis of invasive Candida infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend). Oropharyngeal Candidiasis (OC): (1) Diagnosis of oropharyngeal candidiasis or (2) Diagnosis of Oropharyngeal candidiasis refractory to itraconazole and /or fluconazole.
<b>Age Restrictions</b>	(TAI): Member is 13 years of age or older (OC): Member is 13 years of age or older. (AI, CI): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(All Indications): Prescribed by or in consultation with an infectious disease specialist, transplant specialist, hematologist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUCALA

## Products Affected

- NUCALA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(SA, EGPA, CRSwNP) Will not be used in combination with other biologics for asthma/allergic conditions (e.g., benralizumab [Fasenra], dupilumab [Dupixent], omalizumab [Xolair], reslizumab [Cinqair])
<b>Required Medical Information</b>	Part D is medically necessary when there is documentation of ONE of the following: Severe Asthma with Eosinophilic Phenotype (SA) (Initial): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by one of the following: a) blood eosinophil levels are at least 150 cells/microliter at initiation of therapy (measured within 6 weeks of dosing), or b) blood eosinophil levels at least 300 cells/microliter within the past 12 months. (2) Member has had at least two or more asthma exacerbations requiring systemic corticosteroids within the past 12 months OR member has had any prior intubation for an asthma exacerbation OR Member has had a prior asthma-related hospitalization within the past 12 months, AND (3) Member is currently treated with high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g. long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Initial): (1) Diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA), (2) Member's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy), and (3) Member is currently receiving corticosteroid therapy (e.g. prednisolone, prednisone). Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (Initial): (1) Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP). (2) Unless contraindicated, the member has had an inadequate response to at least a 2 month treatment with an intranasal corticosteroid (e.g. fluticasone, mometasone). (3) Used in combination with another agent for CRSwNP.
<b>Age Restrictions</b>	(SA) (Initial, Reauth): Member is 6 years of age or older. (HES) (Initial, Reauth): Member is 12 years of age or older. (CRSwNP, EGPA) (Initial, Reauth): Member is 18 years of age or older.

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(SA): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist. (EGPA): Prescribed by or in consultation with a rheumatologist. (HES): Prescribed by or in consultation with either allergist/immunologist or hematologist. (CRSwNP): Prescribed by or in consultation with allergist, immunologist, otolaryngologist or pulmonologist.
<b>Coverage Duration</b>	(Initial): 12 months. (Reauth): 12 months.
<b>Other Criteria</b>	Subject to Part B vs Part D review. Hypereosinophilic Syndrome (HES) (Initial): (1) Diagnosis of HES. (2) All of the following: (a) Member has been diagnosed for at least 6 months, (b) Verification that other non-hematologic secondary causes have been ruled out (e.g. drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy), (c) member is FIP1-like1-platelet derived growth factor receptor alpha kinase (FIP1L1-PDGFR kinase)-negative. (3) Member has uncontrolled HES defined by both of the following: (a) Pre-treatment blood eosinophil count greater than or equal to 1000 cells/microliter, (b) Member has experienced 2 or more flares within the past 12 months. (4) Inadequate response or inability to tolerate one of the following: (a) corticosteroid therapy (e.g. prednisone), (b) cytotoxic/immunosuppressive therapy (e.g. hydroxyurea, cyclosporine, imatinib). (SA)(Reauth): (1) Member is currently treated with high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g. long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. (EGPA) (Reauth): (1) Positive clinical response to therapy (e.g. increase in remission time). (HES) (Reauth): (1) Positive clinical response (e.g. reduction in corticosteroid use, reduction of blood eosinophil count, reduction in flares). (CRSwNP) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction of nasal polyps score [NPS: 0-8 scale], improvement in nasal obstruction symptoms via visual analog scale [VAS: 0-10 scale]), (2) Used in combination with another agent for CRSwNP.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUEDEXTA

---

## Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PBA): Presence of cardiac rhythm disorder documented by a cardiac test (e.g. electrocardiogram)
<b>Required Medical Information</b>	Pseudobulbar Affect (PBA): (1) Diagnosis of Pseudobulbar affect (2) Member has one of the following underlying conditions: (a) Amyotrophic lateral sclerosis (b) Multiple sclerosis (c) Alzheimer's disease (d) Parkinson's disease (e) Stroke (f) Traumatic brain injury
<b>Age Restrictions</b>	(PBA): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PBA): Prescribed by or in consultation with a neurologist or psychiatrist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUPLAZID

---

## Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Hallucinations and Delusions Parkinson Disease Psychosis (HDPDP): Inadequate response or inability to tolerate ONE of the following (a) quetiapine or (b) clozapine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	(All Indications): Approve if for continuation of therapy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# NURTEC

## Products Affected

- NURTEC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AM)(Initial, Reauth): Will be used for preventative treatment of migraine. Medication will be used in combination with another oral CGRP inhibitor. (MP) (Initial, Reauth): Will be used for acute treatment of migraine. Medication used in combination with another CGRP inhibitor for the preventive treatment of migraines.
<b>Required Medical Information</b>	Acute Treatment of Migraines (AM)(Initial): (1) Diagnosis of migraine with or without aura in adults. (2) Member has fewer than 15 headache days per month. (3) inadequate response or inability to tolerate ONE generic formulary triptan. Preventative Treatment of Migraines (MP) (Initial): (1) Diagnosis of episodic migraines defined as 4 to 18 migraine days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine
<b>Age Restrictions</b>	(AM)(MP)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AM)(MP)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist.
<b>Coverage Duration</b>	(AM)(MP)(Initial): 6 months. (AM)(MP)(Reauth): 12 months
<b>Other Criteria</b>	(AM)(REAUTH): (1) Positive response to therapy (e.g. reduction in pain, photophobia, phonophobia, nausea). (MP)(Reauth): (1) Positive clinical response to therapy (e.g. reduction in headache frequency and/or intensity, use of acute migraine medications [e.g. nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, naproxen), triptans (e.g. eletriptan, rizatriptan, sumatriptan)] has decreased since the start of CGRP therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	



PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

# OCALIVA

## Products Affected

- OCALIVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Primary biliary cholangitis (PBC): (1) Used in combination with ursodeoxycholic acid (e.g. Urso, Urso Forte, ursodiol), OR (2) inability to tolerate ursodeoxycholic acid. (2) Member has one of the following: (a) no cirrhosis or (b) compensated cirrhosis with no evidence of portal hypertension.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PBC) (Initial, Reauth): Prescribed by or in consultation with a hepatologist or gastroenterologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): Indefinite
<b>Other Criteria</b>	(PCB)(Reauth): Positive clinical response to Ocaliva therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OFEV

## Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): (1) Diagnosis of SSc-ILD confirmed by a high resolution CT scan or biopsy. Chronic Fibrosing Interstitial Lung Disease (ILDs) with progressive phenotype (Initial): (1) Confirmed by high resolution CT scan (HRCT) showing at least 10% of lung volume with fibrotic features, (2) Disease has a progressive phenotype as observed by one of the following: (a) decline of forced vital capacity (FVC), (b) worsening of respiratory symptoms, (c) increased extent of fibrosis seen on imaging.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(IPF, SSc-ILD, ILDs): Prescribed by or in consultation a pulmonologist or lung transplant specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(REAUTH) (IPF, ILDs, SSc-ILD): BOTH of the following (1) stabilization from baseline AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OLUMIANT

## Products Affected

- OLUMIANT ORAL TABLET 1 MG, 4 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, COVID-19, Alopecia Areata): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g., tumor necrosis factor antagonists JAK inhibitors, or potent immunosuppressants such as azathioprine, cyclosporine
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate two of the following: (a) Humira, (b) Enbrel (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia, (f) Cyltezo, (g) Yuflyma OR documentation demonstrating that a trial may be inappropriate. (COVID-19): (1) Diagnosis of COVID-19 (2) Member is hospitalized (3) Member requires one of the following: (a) supplemental oxygen, (b) non-invasive mechanical ventilation, (c) invasive mechanical ventilation, (d) extracorporeal membrane oxygenation (ECMO). Alopecia Areata (AA): (1) Diagnosis of alopecia areata (2) Member has at least 50% scalp hair loss (3) Other causes of hair loss have been ruled out (e.g., androgenetic alopecia, trichotillomania, tinea capitis, psoriasis) (4) Inadequate response or inability to tolerate one previous treatment for alopecia areata (e.g., topical, intralesional, or systemic corticosteroids, topical immunotherapy)
<b>Age Restrictions</b>	(RA, COVID-19, Alopecia Areata): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA): Prescribed by or in consultation with a rheumatologist (AA): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(RA, Alopecia Areata): Indefinite. (COVID-19): 14 days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ONYCHOMYCOSIS AGENTS

## Products Affected

- *tavaborole*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Onychomycosis: (1) Diagnosis of onychomycosis of the toenail(s) due to <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i> . (2) Diagnosis confirmed by one of the following: (a) positive potassium hydroxide (KOH) preparation, (b) culture, or (c) histology. (3) Condition is causing debility or a disruption in member's activities of daily living. (4) Inadequate response or inability to tolerate BOTH of the following: (a) oral generic terbinafine, AND (b) oral generic itraconazole OR topical generic ciclopirox.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OPZELURA

## Products Affected

- OPZELURA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD) (Initial): (1) For short-term, non-continuous treatment of chronic atopic dermatitis. (2) Inadequate response or inability to tolerate at least TWO of the following: (a) topical tacrolimus OR topical pimecrolimus, OR (b) generic, prescription medium potency or higher topical steroid, OR (c) Eucrisa. (3) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g. azathioprine or cyclosporine). Nonsegmental Vitiligo (NV)(Initial): (1) Diagnosis of nonsegmental vitiligo (2) Inadequate response or inability to tolerate one of the following (a) medium or higher potency topical corticosteroid (b) pimecrolimus cream (c) tacrolimus ointment (3) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g., azathioprine or cyclosporine).
<b>Age Restrictions</b>	(AD, NV): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AD) (Initial, Reauth): Prescribed by or in consultation with a dermatologist or allergist/immunologist (NV) (Initial, Reauth): Prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	(AD)(Initial): 8 Weeks, (Reauth): End of contract year (NV)(Initial): 6 months, (Reauth): 12 months
<b>Other Criteria</b>	(AD) (Reauth): Positive clinical response to therapy. (NV)(Reauth): (1) Documentation of positive clinical response to therapy (2) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g., azathioprine or cyclosporine).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL ANTIBIOTICS

## Products Affected

- NUZYRA
- SIVEXTRO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Documentation of a current bacterial infection and an inadequate response or inability to tolerate TWO antibiotics to which the organism is susceptible OR the requested medication is the only antibiotic to which the organism is susceptible.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with an infectious disease specialist OR oncologist
<b>Coverage Duration</b>	(Initial, Reauth): 1 month
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable. (REAUTH): Prescriber attests that an infectious disease consult determines that a longer duration of therapy is required.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL CHEMO AGENTS

---

## Products Affected

- *abiraterone acetate* 420 MG
- AKEEGA
- ALECENSA
- ALUNBRIG
- AUGTYRO
- AYVAKIT
- BALVERSA
- *bexarotene*
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX
- CALQUENCE ORAL TABLET
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*
- EXKIVITY
- FOTIVDA
- FRUZAQLA
- GAVRETO
- *gefitinib*
- GILOTRIF
- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate*
- IMBRUVICA ORAL CAPSULE
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG,
- INLYTA
- INQOVI
- INREBIC
- IWILFIN
- JAKAFI
- JAYPIRCA
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KOSELUGO
- KRAZATI
- *lapatinib ditosylate*
- *lenalidomide*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LUMAKRAS
- LYNPARZA ORAL TABLET
- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)
- MEKINIST
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO
- OJJAARA
- ONUREG
- ORGOVYX



- ORSERDU
- *pazopanib hcl*
- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- QINLOCK
- RETEVMO
- REVLIMID
- REZLIDHIA
- ROZLYTREK ORAL CAPSULE
- RUBRACA
- RYDAPT
- SCEMBLIX
- *sorafenib tosylate*
- SPRYCEL
- STIVARGA
- *sunitinib malate*
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID
- TIBSOVO
- TRUQAP
- TUKYSA
- TURALIO ORAL CAPSULE 125 MG
- VANFLYTA
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- VONJO
- VOTRIENT
- WELIREG
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- ZEJULA ORAL TABLET
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as ??off label?? with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL PAH AGENTS

## Products Affected

- OPSUMIT
- ORENITRAM MONTH 1
- ORENITRAM MONTH 2
- ORENITRAM MONTH 3

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORENCIA SQ

## Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, pJIA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Polyarticular Juvenile idiopathic arthritis (pJIA): (1) Diagnosis of JIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine.
<b>Age Restrictions</b>	(Pjia, PsA): Member is 2 years of age or older. (RA): member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, pJIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORIAHNN

## Products Affected

- ORIAHNN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Uterine Leiomyomas (UL)(Initial): (1) Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), (2) Member is premenopausal, (3) ONE of the following: (a) Inadequate response or inability to tolerate one of the following for no more than 30 days: combination (estrogen/progestin) contraceptive, progestins, tranexamic acid, OR (b) Member has had a previous interventional therapy to reduce bleeding (e.g. uterine-artery embolization and magnetic resonance-guided focused ultrasonography), (4) Treatment duration of therapy has not exceeded a total of 24 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(UL) (Reauth): (1) Member has improvement in bleeding associated with uterine leiomyomas (fibroids) (e.g. significant/sustained reduction in menstrual blood loss per cycle, improved quality of life, etc.), (2) Treatment duration of therapy has not exceeded a total of 24 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORKAMBI

## Products Affected

- ORKAMBI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(CF): Diagnosis of CF other than those homozygous for the F508del mutation
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of CF, (2) Member is homozygous for the F508del mutation in the CFTR gene (3) If the member's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene
<b>Age Restrictions</b>	(CF): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORLADEYO

---

## Products Affected

- ORLADEYO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Hereditary Angioedema (HAE): (1) Diagnosis of HAE, (2) For prophylaxis against HAE attacks.
Age Restrictions	(HAE): Member is 12 years of age or older
Prescriber Restrictions	(HAE): Prescribed by or in consultation with an immunologist, allergist or pulmonologist
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# OTEZLA

## Products Affected

- OTEZLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Oral Ulcers Associated with Bechet's Disease (OU-BD): (1) Diagnosis of OU-BD. (2) Inadequate response or inability to tolerate ONE topical corticosteroid (e.g. triamcinolone acetonide dental paste) AND ONE systemic corticosteroid. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Plaque psoriasis (PsO): (1) Diagnosis of PsO.
<b>Age Restrictions</b>	(PsA, PsO, OU-BD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsA, OU-BD): Prescribed by or in consultation with a Rheumatologist or Dermatologist. (PsO): Prescribed by or in consultation with dermatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# OXBRYTA

## Products Affected

- OXBRYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(SCD)(Initial, Continuation): Concurrent therapy with Adakveo (crizanlizumab-tmca)
<b>Required Medical Information</b>	Sickle Cell Disease (SCD) (Initial): (1) Diagnosis of sickle cell disease, (2) Member had at least 1 vaso-occlusive crisis (VOC) event within the past 12 months (e.g. acute painful crisis, acute chest syndrome,) (3) Hemoglobin level that is between 5.5 g/dL and 10.5 g/dL prior to therapy initiation (4) Inadequate response or inability to tolerate hydroxyurea (i.e., Siklos, Droxia).
<b>Age Restrictions</b>	(SCD)(Initial, Continuation): Member is 4 years of age or greater
<b>Prescriber Restrictions</b>	(SCD)(Initial, Continuation): Prescribed by or in consultation with a hematologist, oncologist, or specialist with expertise in the diagnosis and management of sickle cell disease
<b>Coverage Duration</b>	(Initial, Continuation): 12 months
<b>Other Criteria</b>	(SCD)(Continuation): Member has had a positive clinical response to Oxbryta therapy (e.g. an increase in hemoglobin level of greater than or equal to 1 g/dL from baseline, decreased annualized incidence rate of VOCs)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## PART D VS EXCLUDED

---

### Products Affected

- OSPHENA
- *voriconazole intravenous*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

## PDE INHIBITOR AGENTS FOR PAH

### Products Affected

- ALYQ
- *tadalafil (pah)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, (4) inadequate response or inability to tolerate generic tadalafil (Applies to Brand Adcirca only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(Initial): Prescribed by or in consultation with Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(PAH)(Reauth): (1) Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PRALUENT

## Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia, (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p> <p>Atherosclerotic cardiovascular disease (ASCVD) (Initial): (1) Diagnosis of atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid), (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months (Continuation): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Homozygous Familial Hypercholesterolemia (HoFH) (Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300 mg/dL. (3) Member is receiving other lipid-lowering therapy (e.g. statin, ezetimibe). (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASVCD)(CONTINUATION): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (HoFH)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy (e.g. statin, ezetimibe). (3) Not used in combination with Juxtapid (lomitapide).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PREFERRED HEPATITIS C AGENTS

---

## Products Affected

- EPCLUSA
- HARVONI ORAL PACKET
- HARVONI ORAL TABLET 90-400 MG
- MAVYRET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) Documentation of member's Hepatitis C Genotype. (2) Prescribed regimen is consistent with the current AASLD/IDSA guidance.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Duration will be applied consistent with AASLD/ IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PRETOMANID

## Products Affected

- *pretomanid*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Multidrug Resistant Tuberculosis (MDRTB): (1) Diagnosis of pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive MDRTB. (2) Medication will be used as part of a combination regimen with bedaquiline (Sirturo??) and linezolid.
<b>Age Restrictions</b>	(MDRTB): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	26 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROCYSBI

## Products Affected

- PROCYSBI ORAL PACKET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(NC) (Initial, Reauth): Hypersensitivity to penicillamine
<b>Required Medical Information</b>	Nephrotic Cystinosis (NC) (Initial): (1) Diagnosis of nephrotic cystinosis, (2) inadequate response or titration from cysteamine bitartrate immediate-release capsules (Cystagon), (3) documentation of baseline WBC and alkaline phosphatase levels.
<b>Age Restrictions</b>	(NC): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(NC)(Initial, Reauth): Prescribed by or in consultation with a nephrologist.
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): 6 months.
<b>Other Criteria</b>	(NCB)(REAUTH): The prescriber has evaluated all of the following since the initiation of treatment: (1) ONE of the following: (a) WBC cysteine level or (b) plasma cysteamine level, (2) WBC count, AND (3) alkaline phosphatase level.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PROLIA

## Products Affected

- PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Part D is medically necessary when all of the following criteria are met:</p> <p>Osteoporosis (OS) (Initial): ALL of the following: (1) Diagnosis of osteoporosis confirmed by one of the following: (a) T-score less than or equal to -2.5 (b) history of osteoporotic fracture (e.g. vertebral, hip, non-vertebral) or (c) multiple risk factors for fracture. (2) ONE of the following: (a) inadequate response or inability to tolerate at least one other osteoporosis medicine (e.g. oral bisphosphonates, calcitonin, estrogens, selective estrogen receptor modulator (SERMs)) or (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted or (c) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less). Osteopenia (OPN) (Initial): BOTH of the following: (1) Diagnosis of osteopenia confirmed by a T-score less than -1.0, but greater than -2.5. (2) One of the following: (a) Member is receiving adjuvant aromatase inhibitor therapy for breast cancer (b) member is receiving androgen deprivation therapy for non-metastatic prostate cancer. Prophylaxis of Postmenopausal Osteoporosis (PO) (Initial): BOTH of the following: (1) BMD T score less than -1.0 and greater than -2.5. (2) ONE of the following: (a) Inadequate response or inability to tolerate an oral bisphosphonates or a selective estrogen receptor modulator (SERMs) or (b) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less) not receiving dialysis or diagnosed with stage 5 kidney disease.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to Part B vs Part D review. Glucocorticoid Induced Osteoporosis (GCO)(Initial): ALL of the following: (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) ONE of the following: (a)Inadequate response or inability to tolerate ONE of the following: (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs)., (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted, (c) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROMACTA

## Products Affected

- PROMACTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Chronic Idiopathic Thrombocytopenic Purpura (ITP)(Initial): (1) Diagnosis of relapsed/refractory, persistent, or chronic ITP. (2) Baseline platelet count is less than 30,000/mcL. (3) Member's degree of thrombocytopenia and clinical condition increase the risk of bleeding. (4) Inadequate response or inability to tolerate ONE of the following: (a) corticosteroids, (b) immune globulin, (c) splenectomy. First-Line for Severe Aplastic Anemia(FLSAA): (1) Diagnosis of severe aplastic anemia. (2) Used for first-line treatment (i.e., member has not received prior immunosuppressive therapy). (3) Member meets at least TWO of the following: (a) absolute neutrophil count less than 500/mcL, (b) platelet count less than 20,000/mcL, (c) absolute reticulocyte count less than 60,000/mcL. (4) Used in combination with standard immunosuppressive therapy (e.g. Atgam [antithymocyte globulin equine] and cyclosporine). Refractory Severe Aplastic Anemia (RSAA)(Initial): (1) Diagnosis of refractory severe aplastic anemia. (2) Member has a platelet count less than 30,000/mcL. (3) Inadequate response or inability to tolerate immunosuppressive therapy with antithymocyte globulin and cyclosporine. Chronic Hepatitis C-Associated Thrombocytopenia (HEPC-TP): (1) Diagnosis of chronic hepatitis C-associated thrombocytopenia. (2) One of the following: (a) Planning to initiate and maintain interferon-based treatment, or (b) currently receiving interferon-based treatment.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ITP, FLSAA, RSAA)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist. (HEPC-TP)(Initial, Continuation): Prescribed by or in consultation with Hematologist/oncologist, Gastroenterologist, Hepatologist, Infectious disease specialist, HIV specialist.
<b>Coverage Duration</b>	(ITP)Initial,Cont.=12mo.(FLSAA)=6mo.(RSAA)Initial=6mo.(HEPC-TP)Initial=3mo.(RSAA,HEPC-TP)Cont.=12mo.

PA Criteria	Criteria Details
<b>Other Criteria</b>	(ITP, RSAA)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. (HEPC-TP)(Continuation): (1) ONE of the following: (A) For members that started treatment with Promacta prior to initiation of treatment with interferon, both of the following: (i) Member is currently on antiviral interferon therapy for treatment of chronic hepatitis C, AND (ii) member reached a threshold platelet count that allows initiation of antiviral interferon therapy with Promacta treatment by week 9. (B) For members that started treatment with Promacta while on concomitant treatment with interferon, member is currently on antiviral interferon therapy for treatment of chronic hepatitis C.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PYRUKYND

## Products Affected

- PYRUKYND
- PYRUKYND TAPER PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hemolytic anemia with pyruvate kinase deficiency (HAWPKD) (Initial): (1) Diagnosis of hemolytic anemia confirmed by the presence of chronic hemolysis (e.g., increased indirect bilirubin, elevated lactated dehydrogenase [LDH], decreased haptoglobin, increased reticulocyte count) (2) Diagnosis of pyruvate kinase deficiency confirmed by molecular testing of ALL of the following mutations on the PKLR gene: (a) Presence of at least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene, of which at least 1 was a missense variant, (b) Member is not homozygous for the c. 1436G A (p.R479H) variant, (c) Member does not have 2 non-missense variants (without the presence of another missense variant) in the PKLR gene (3) Hemoglobin is less than or equal to 10g/dL (4) Member has symptomatic anemia or is transfusion dependent (5) Other causes of hemolytic anemia (e.g., infections, toxins, drugs) have been ruled out.
<b>Age Restrictions</b>	(HAWPKD) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(HAWPKD) (Initial, Reauth): Prescribed by or in consultation with a hematologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(HAWPKD)(Reauth): (1) Documentation of positive clinical response to therapy, improvement in markers of hemolysis from baseline (e.g., bilirubin, lactated dehydrogenase [LDH], haptoglobin, reticulocyte count).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# QBREXZA

---

## Products Affected

- QBREXZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Hyperhidrosis: (1) Hyperhidrosis Disease Severity Scale grade 3 or 4.
Age Restrictions	(Hyperhidrosis): Member is 9 years of age or older
Prescriber Restrictions	(Hyperhidrosis): Prescribed by or in consultation with a dermatologist, primary care physician, internist, or pediatrician.
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# QUALAQUIN

## Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Uncomplicated Malaria: (1) Diagnosis of uncomplicated malaria due to (a) plasmodium falciparum malaria or (b) plasmodium vivax . (2) One of the following: (a) Both of the following: (i) treatment in areas of chloroquine-sensitive malaria (ii) Inadequate response or inability to tolerate chloroquine or hydroxychloroquine, or (b)treatment in areas of chloroquine-resistant malaria. Babesiosis: (1) Diagnosis of babesiosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Babesiosis: 10 days Uncomplicated Malaria: 14 Days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RADICAVA

## Products Affected

- RADICAVA ORS STARTER KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Amyotrophic Lateral Sclerosis (ALS)(Initial): (1) Diagnosis of definite or probable ALS per the revised El Escorial World Federation of Neurology criteria. (2) Time from symptom onset is 2 years or less. (3) Normal respiratory function defined as forced vital capacity (FVC) of greater than or equal to 80% at the start of treatment. (4) Scores of 2 points or greater on each individual item of the ALS Functional Rating Scale-revised (ALSFRS-R).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ALS)(Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): 6 months.
<b>Other Criteria</b>	(ALS)(Reauth): (1) Member shows benefit from therapy (e.g. slowing of decline of functional abilities).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# RAVICTI

## Products Affected

- RAVICTI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(UCD): Acute hyperammonemia. N-acetylglutamate synthase (NAGS) deficiency
<b>Required Medical Information</b>	Urea Cycle Disorder (UCD): (1) Diagnosis of urea cycle disorder involving deficiencies of carbamoyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), or argininosuccinic acid synthetase (AAS) confirmed via enzymatic, biochemical, or genetic testing. (2) Inadequate response or inability to tolerate sodium phenylbutyrate.
<b>Age Restrictions</b>	(UCD): Member is 2 months of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RECORLEV

## Products Affected

- RECORLEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cushing's Syndrome (CS) (Initial): (1) Diagnosis of Cushing's syndrome (2) Member is being treated for endogenous hypercortisolemia (e.g., pituitary adenoma, ectopic tumor, adrenal adenoma) (3) One of the following: (a) Member is not a candidate for surgery, (b) surgery has not been curative (4) Inadequate response or inability to tolerate oral ketoconazole
<b>Age Restrictions</b>	(CS) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CS) (Initial) (Reauth): Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	(Initial) (Reauth): 12 months
<b>Other Criteria</b>	(CS) (Reauth): (1) Documentation of positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# REPATHA

## Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia. Atherosclerotic cardiovascular disease (ASCVD)(Initial): (1) Diagnosis of ASCVD confirmed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid). (HLA, ASCVD) (Initial): ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months.
<b>Other Criteria</b>	Homozygous Familial Hypercholesterolemia (HoFH) (Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300 mg/dL. (3) Member is receiving other lipid-lowering therapy (e.g. statin, ezetimibe). (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASCVD)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (HoFH)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy (e.g. statin, ezetimibe). (3) Not used in combination with Juxtapid (lomitapide).
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# RESPIRATORY ENZYMES

## Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG
- ZEMAIRA INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG
- PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(ATT): (1) IgA deficiency with known anti-IgA antibody.
<b>Required Medical Information</b>	Part D is medically necessary when ALL of the following are met: Congenital Alpha-1 Antitrypsin Deficiency (ATT): (1) Diagnosis of congenital alpha1-antitrypsin deficiency confirmed by one of the following: (a) PiZZ, PiZ(null) or Pi(null)(null) protein phenotypes (homozygous) or (b) Other rare AAT disease-causing alleles associated with serum alpha1-antitrypsin (AAT) level less than 11??mol/L. (2) Low serum concentration of alpha-1 antitrypsin defined as less than 35 percent of normal (less than 80 mg/dL or less than 11 uM/L or less than 0.8 g/L). (3) the member has progressive panacinar emphysema with a documented rate of decline in forced expiratory volume in 1 second (FEV 1)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# REZUROCK

## Products Affected

- REZUROCK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic graft-versus-host disease (cGVHD) (Initial): (1) Diagnosis of chronic graft-versus-host disease, (2) Inadequate response or inability to tolerate two or more lines of systemic therapy (e.g. corticosteroids, mycophenolate, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(cGVHD) (Initial/Reauth): Prescribed by or in consultation with one of the following (1) Hematologist, (2) Oncologist, (3) physician experienced in the management of transplant patients
<b>Coverage Duration</b>	(Initial/Reauth): 12 months
<b>Other Criteria</b>	(cGVHD) (Reauth): (1) Member does not show evidence of progressive disease while on therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RINVOQ

## Products Affected

- RINVOQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, AD, UC, AS, nr-AxSPA, CD): Concurrent use with any other biologic disease modifying anti-rheumatic drug (DMARD), other JAK inhibitors, or potent immunosuppressants (e.g. azathioprine, cyclosporine).
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severely active RA. (2) Member has inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine) (3) Member had inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Cyltezo, Yuflyma) OR documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate at least one DMARD (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine) (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Cyltezo, Yuflyma) or documentation demonstrating that a trial may be inappropriate. Atopic Dermatitis (AD): (1) Diagnosis of moderate to severe atopic dermatitis, (2) Inadequate response or inability to tolerate at least one of the following: (a) medium or higher potency topical corticosteroid, (b) pimecrolimus cream, (c) tacrolimus cream, (d) Eucrisa (crisaborole) ointment (3) Inadequate response or inability to tolerate at least one systemic drug product for the treatment of atopic dermatitis (examples include, but are not limited to Dupixent, Adbry or documentation that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of Ulcerative Colitis (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine). (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Humira, Cyltezo, Yuflyma) or documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(RA, PsA, UC, AS, nr-AxSPA, CD): Member is 18 years of age or older (AD): Member is 12 years of age or older.
<b>Prescriber Restrictions</b>	(RA, AS, nr-AxSPA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist. (UC, CD): Prescribed by or in consultation with a gastroenterologist.

PA Criteria	Criteria Details
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of active ankylosing spondylitis. (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g., Enbrel, Humira, Cyltezo, Yuflyma) OR documentation demonstrating that a trial may be inappropriate. Non-radiographic axial spondyloarthritis (nr-AxSPA): (1) Diagnosis of nr-AxSPA (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g., Enbrel, Humira, Cimzia, Cyltezo, Yuflyma) or documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID. Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g., corticosteroid, methotrexate, azathioprine or 6-mercaptopurine) (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g., Enbrel, Humira, Cyltezo, Yuflyma) OR documentation demonstrating that a trial may be inappropriate.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# SAMSCA

---

## Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Hyponatremia: (1) Members who are unable to sense or appropriately respond to thirst, (2) hypovolemic hyponatremia, (3) concomitant use of strong CYP3A inhibitors
<b>Required Medical Information</b>	Hyponatremia: (1) Diagnosis of clinically significant hypervolemic or euvolemic hyponatremia.
<b>Age Restrictions</b>	Hyponatremia: Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	Hyponatremia: Prescribed by or in consultation with a cardiologist, endocrinologist or nephrologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIGNIFOR

## Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cushing's disease (CD)(Initial): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative
<b>Age Restrictions</b>	(CD)(Initial): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CD)(Initial, Reauth): Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CD)(Reauth): Documentation of positive clinical response (e.g. clinically meaningful reduction in 24- hour urinary free cortisol levels, improvement in signs or symptoms of the disease)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SILDENAFIL

## Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH, RP): Documentation of concomitant nitrate use
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Mean pulmonary artery pressure greater than or equal 25 mm Hg at rest or greater than 30 mm Hg with exertion. Raynaud's Phenomenon (RP): (1) Diagnosis of secondary Raynaud's phenomenon. (2) Inadequate response or inability to tolerate a calcium channel blocker.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH, RP): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIRTURO

## Products Affected

- SIRTURO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB): (1) Diagnosis of MDR-TB. (2) Member weighs at least 15kg (applies to members 5 to less than 18 years of age). (3) One of the following: (a) Medication will be used in combination with at least 3 other drugs to which the member's MDR-TB isolate has been shown to be susceptible in vitro OR (b) If in vitro testing results are unavailable, treatment will be initiated in combination with at least 4 other drugs to which the member's MDR-TB isolate is likely to be susceptible. (4) Sirturo (bedaquiline) will be administered by directly observed therapy (DOT).
<b>Age Restrictions</b>	(MDR-TB): Member is 5 years of age or older.
<b>Prescriber Restrictions</b>	(MDR-TB): Prescribed by or in consultation with infectious disease specialist or pulmonologist
<b>Coverage Duration</b>	24 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYCLARYS

## Products Affected

- SKYCLARYS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Friedreich Ataxia (FA)(Initial): (1) Diagnosis of Friedreich Ataxia (FA) confirmed by genetic testing demonstrating mutation in the FXN gene (2) Member has a Modified Friedreich's Ataxia Rating Scale (mFARS) score of greater than or equal to 20 and less than or equal to 80 (3) Member has B-type natriuretic peptide value less than or equal to 200 pg/ml
<b>Age Restrictions</b>	(FA)(Initial)(Reauth): member is 16 years of age or older
<b>Prescriber Restrictions</b>	(FA)(Initial)(Reauth): Prescribed by or in consultation with one of the following specialists: neurologist, neurogeneticist, Psychiatrist (Physical Medicine and Rehabilitation Specialist)
<b>Coverage Duration</b>	(Initial): 12 months (Reauth): 12 months
<b>Other Criteria</b>	(FA)(Reauth): (1) Documentation of positive clinical response to therapy as evidenced by one of the following: (a) an increase in peak work (in Watts/kg) during exercise testing from baseline (b) a decrease in the rate of progression of Modified Friedreich's Ataxia Rating Scale (mFARS)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYRIZI SC

## Products Affected

- SKYRIZI PEN
- SKYRIZI SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA, CD): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque psoriasis (PsO):Diagnosis of moderate to severe PsO. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Crohn??s Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g., corticosteroid, methotrexate, azathioprine or 6-mercaptopurine).
<b>Age Restrictions</b>	(PsO, PsA, CD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation a dermatologist (PsA): Prescribed by or consultation with a rheumatologist or dermatologist (CD): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Part B drug applies only to beneficiaries enrolled in an MA-PD plan.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYTROFA

## Products Affected

- SKYTROFA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Growth Failure in Children (GFC)(Initial): (1) Diagnosis of growth hormone deficiency confirmed by one of the following: (a) Height is documented by one of the following (utilizing age and gender growth charts related to height): (i) Height is greater than 2.0 standard deviations [SD] below midparental height (ii) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender). (2) Growth velocity is greater than 2 SD below mean for age and gender. (3) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g. delayed is greater than 2 years compared with chronological age). (4) documentation of bone age, abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine.
<b>Age Restrictions</b>	(GFC) (Initial, Reauth): Member is 1 years of age or greater
<b>Prescriber Restrictions</b>	(GFC)(Initial): Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	(Initial, Continuation): 12 months
<b>Other Criteria</b>	(GFC) (Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# STELARA SQ

## Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(CD, UC, PsA, PsO): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Part D is medically necessary when: Plaque psoriasis (PsO): Diagnosis of moderate to severe PsO. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine). Ulcerative Colitis (UC): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine).
<b>Age Restrictions</b>	(CD, UC): Member is 18 years of age or older. (PsO, PsA): Member is 6 years of age or older.
<b>Prescriber Restrictions</b>	(CD, UC): prescribed by or in consultation with a Gastroenterologist. (PsO): prescribed by or in consultation with a Dermatologist. (PsA): prescribed by or in consultation with a Dermatologist or Rheumatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# SYMDEKO

## Products Affected

- SYMDEKO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis. (2) One of the following: a) Member is homozygous for the F508del mutation, or b) Member has at least one tezacaftor/ivacaftor responsive mutation in the CFTR gene. (3) If the member's genotype is unknown, an FDA-cleared test must be used to detect the presence of CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test
<b>Age Restrictions</b>	(CF): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with a pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SYMLIN

## Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION  
PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION  
PEN-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(DM): Gastroparesis.
<b>Required Medical Information</b>	Diabetes Mellitus (DM): (1) Diagnosis of diabetes (Type 1 or Type 2). (2) inadequate response to optimal insulin monotherapy. (3) concurrent use of mealtime insulin.
<b>Age Restrictions</b>	(DM): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TADLIQ

## Products Affected

- TADLIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, (4) inadequate response or inability to tolerate generic tadalafil
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(Initial): Prescribed by or in consultation with Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(PAH)(Reauth): (1) Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TAFAMIDIS

## Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)(Initial): (1) Diagnosis of ATTR-CM confirmed by one of the following: (a) Member has a transthyretin (TTR) mutation (e.g. V122I), (b) cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits, or (c) all of the following: echocardiogram or cardiac magnetic resonance image suggestive of amyloidosis, scintigraphy scan suggestive of cardiac TTR amyloidosis, and absence of light-chain amyloidosis, (2) One of the following: (a) History of heart failure (HF), with at least one prior hospitalization for HF, or (b) presence of clinical signs and symptoms of HF (e.g. dyspnea, edema), (3) Member has New York Heart Association (NYHA) Functional Class I, II, or III heart failure
<b>Age Restrictions</b>	(ATTR-CM) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(ATTR-CM) (Initial, Reauth): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(ATTR-CM)(Reauth): (1) Positive clinical response to therapy, (2) Member continues to have NYHA Functional Class I, II, or III heart failure.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TALTZ

## Products Affected

- TALTZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA, AS, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	<p>Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) ONE of the following: (A) For members 6 to 17 years of age: an inadequate response or inability to tolerate two of the following: (a) Enbrel, (b) Cosentyx, (c) Stelara or documentation demonstrating that a trial may be inappropriate, OR (B) For members 18 years of age or older: an inadequate response or inability to tolerate two of the following: (a) Cosentyx (b) Enbrel (c) Humira (d) Skyrizi, (e) Stelara, (f) Otezla, (g) Cyltezo, (h) Yuflyma or documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Enbrel (b) Humira (c) Cosentyx (d) Rinvoq (e) Skyrizi (f) Stelara (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla, (j) Cyltezo, (k) Yuflyma OR documentation demonstrating that a trial may be inappropriate. Ankylosing spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate TWO of the following: (a) adalimumab (Humira), (b) etanercept (Enbrel), (c) secukinumab (Cosentyx), (d) upadacitinib (Rinvoq), (e) tofacitinib (Xeljanz/Xeljanz XR), (f) adalimumab-adbm (Cyltezo), (g) adalimumab-aaty (Yuflyma) OR documentation demonstrating that a trial may be inappropriate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate Rinvoq OR Cosentyx OR documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID (e.g. ibuprofen, meloxicam, naproxen).</p>
<b>Age Restrictions</b>	(PsA, AS, nr-axSpA): Member is 18 years of age or older. (PsO): Member is 6 years of age or older.
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TARPEYO

## Products Affected

- TARPEYO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Immunoglobulin A nephropathy (IgAN): (1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) (2) Member is at risk of rapid disease progression [e.g., generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g, or by other criteria such as clinical risk scoring using the international IgAN Prediction Tool] (3) Used to reduce proteinuria (4) Estimated glomerular filtration rate (eGFR) greater than or equal to 35 ml/min/1.73 m <sup>2</sup> (5) One of the following: (a) Member has been on a minimum 90-day trial of maximally tolerated dose and will continue to receive therapy with one of the following: (i) an angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril), (ii) An angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan), (b) Member is unable to tolerate both ACE inhibitors and ARBs (6) Inadequate response or inability to tolerate another glucocorticoid (e.g., prednisone, methylprednisolone)
<b>Age Restrictions</b>	(IgAN): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(IgAN): Prescribed by or in consultation with a nephrologist
<b>Coverage Duration</b>	9 months
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TAVNEOS

## Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) (ANCA-V(GPA)(MPA))(Initial): (1) Diagnosis of Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) AND 2) Used as adjunct to standard therapy, and glucocorticoids
<b>Age Restrictions</b>	(ANCA-V(GPA)(MPA))(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(ANCA-V(GPA)(MPA))(Initial, Reauth): Prescribed by or in consultation with a nephrologist, pulmonologist, or rheumatologist.
<b>Coverage Duration</b>	(Initial): 6 Months (Reauth): 1 year
<b>Other Criteria</b>	(ANCA-V(GPA)(MPA))(Reauth): (1) Positive clinical response to therapy defined as sustained remission as assessed by the Birmingham Vasculitis Activity Score (BVAS). (2) Used as adjunct to standard therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TERIPARATIDE

## Products Affected

- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 600 MCG/2.4ML
- *teriparatide (recombinant) subcutaneous solution pen-injector 620 mcg/2.48ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Primary or Hypogonadal Osteoporosis (HGO)(Initial): (1) Diagnosis of HGO in men. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T-score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. hip, spine, etc.). (3) Inadequate response or inability to tolerate (a) bisphosphonates or (b) hormone replacement therapy. Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. hip, spine, etc.). (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia). Glucocorticoid Induced Osteoporosis (GCO)(Initial): (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), or (d) Denosumab (Prolia).</p>
<b>Age Restrictions</b>	(HGO, PMO, GCO) (Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial and Reauth): Remainder of contract year
<b>Other Criteria</b>	(HGO, PMO, GCO) (Reauth): One of the following: (1) Cumulative lifetime therapy does not exceed 2 years [applies to Teriparatide and Forteo], OR (2) member remains at or has returned to having a high risk for fracture despite a total of 24 months of use of parathyroid hormones [applies to Forteo only].

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TESTOSTERONE PRODUCTS

## Products Affected

- JATENZO 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%),
- testosterone cypionate intramuscular solution 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5  
100 mg/ml, 200 mg/ml mg/2.5gm (1.62%), 50 mg/5gm (1%)
- testosterone enanthate intramuscular solution • testosterone transdermal solution
- testosterone transdermal gel 10 mg/act (2%), • TLANDO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Delayed Puberty (DP): (1) Diagnosis of delayed puberty in male members (Applies to Testosterone Enanthate only). Breast Cancer (BC): (1) Diagnosis of inoperable breast cancer in female members (Applies to Testosterone Enanthate only). Hypogonadism (HG)(New starts only): (1) Attestation that diagnosis was initially confirmed by ALL of the following: (A) Two early morning total testosterone levels below 300 ng/dL measured on separate occasions, (B) Normal Prolactin Level, and (C) Physical or cognitive symptoms of testosterone deficiency (e.g. physical: fatigue, sleep disturbances, decreased activity, cognitive: depressive symptoms, cognitive dysfunction, loss of concentration, poor memory, irritability), (2) ONE of the following (A) negative history of prostate and breast cancer OR (B) Both of the following (i) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (ii) documentation that the risk versus benefit has been assessed.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(DP, BC): Indefinite (HG)(New Starts, Continuation): Indefinite
<b>Other Criteria</b>	(HG)(Continuation): ONE of the following (1) negative history of prostate and breast cancer OR (2) Both of the following (a) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (b) documentation that the risk versus benefit has been assessed.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TOPICAL CHEMO AGENTS

## Products Affected

- *bexarotene*
- VALCHLOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as ??off label?? with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TOPICAL RETINOID PRODUCTS

---

## Products Affected

- *adapalene external cream*
- *adapalene external gel 0.3 %*
- *adapalene-benzoyl peroxide external gel*
- *tretinoin external*

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# TRACLEER

## Products Affected

- *bosentan*
- TRACLEER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. (4) Inadequate response or inability to tolerate bosentan (applies to brand Tracleer only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TREMFYA

## Products Affected

- TREMFYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque psoriasis (PsO): (1) Diagnosis or moderate to severe PsO. (2) Inadequate response or inability to tolerate two of the following: (a) Cosentyx, (b) Enbrel, (c) Humira, (d) Skyrizi, (e) Stelara, (f) Otezla, (g) Cyltezo, (h) Yuflyma OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate TWO of the following: (a) Humira (b) Enbrel (c) Cosentyx (d) Rinvoq (e) Skyrizi (f) Stelara (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla, (j) Cyltezo, (k) Yuflyma or documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(PsO, PsA): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIKAFTA

---

## Products Affected

- TRIKAFTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Member has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene as detected by an FDA-cleared cystic fibrosis mutation test OR a mutation in the CFTR gene that is responsive based on in vitro data.
<b>Age Restrictions</b>	(CF): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with a pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TYMLOS

## Products Affected

- TYMLOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. hip, spine, etc.). (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia). Osteoporosis at high risk for fracture in men (OSTm) (Initial): (1) Diagnosis of primary or hypogonadal osteoporosis (2) Both of the following: (a) Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) (b) One of the following (i) History of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm (ii) inadequate response or inability to tolerate at least one osteoporosis treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab])</p>
<b>Age Restrictions</b>	(PMO, OSTm) (Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial and Reauth): Remainder of contract year
<b>Other Criteria</b>	(PMO, OSTm)(Reauth): Cumulative lifetime therapy does not exceed 2 years
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TYVASO DPI

## Products Affected

- TYVASO DPI MAINTENANCE KIT INHALATION  
POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG
- TYVASO DPI TITRATION KIT INHALATION  
POWDER 16 & 32 & 48 MCG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (Initial): (1) Diagnosis of pulmonary hypertension associated with interstitial lung disease (PHILD) WHO Group 3. (2) Diagnosis confirmed by diagnostic test(s) (e.g., right heart catheterization, doppler echocardiogram, computerized tomography imaging)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(PH-ILD)(Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months.
<b>Other Criteria</b>	(PAH)(PH-ILD)(CONTINUATION): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# UBRELVY

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AM)(Initial, Reauth): Will be used for preventative treatment of migraine. Medication will be used in combination with another oral CGRP inhibitor.
<b>Required Medical Information</b>	Acute Treatment of Migraines (AM)(Initial): (1) Diagnosis of migraine with or without aura in adults. (2) Member has fewer than 15 headache days per month. (3) inadequate response or inability to tolerate ONE generic formulary triptan.
<b>Age Restrictions</b>	(AM)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AM)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist.
<b>Coverage Duration</b>	(AM)(Initial): 6 months. (AM)(Reauth): 12 months
<b>Other Criteria</b>	(AM)(REAUTH): (1) Positive response to therapy (e.g. reduction in pain, photophobia, phonophobia, nausea)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VENTAVIS

## Products Affected

- VENTAVIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when ALL of the following are met: Pulmonary Arterial Hypertension(PAH) (Initial): (1)Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class III to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months.
<b>Other Criteria</b>	Subject to Part B vs Part D review. (PAH)(CONTINUATION): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VIJOICE

## Products Affected

- VIJOICE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PROS) (Initial): (1) Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS) (2) Documentation of mutation in the PIK3CA gene (3) Documentation of severe clinical manifestations (e.g., Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal [CLOVES], Facial Infiltrating Lipomatosis [FIL], Klippel-Trenaunay Syndrome [KTS], Megalencephaly-Capillary Malformation Polymicrogyria [MCAP])
<b>Age Restrictions</b>	(PROS) (Initial, Reauth): member is 2 years of age or older
<b>Prescriber Restrictions</b>	(PROS) (Initial, Reauth): Prescribed by or in consultation with a physician who specializes in the treatment of PROS
<b>Coverage Duration</b>	Initial: 6 months. Reauthorization: 12 months
<b>Other Criteria</b>	(PROS) (Reauth): (1) Documentation of positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VOXZOGO

## Products Affected

- VOXZOGO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Achondroplasia) (Initial): (1) Member has open epiphyses, (2) Diagnosis of achondroplasia as confirmed by both of the following, (i) Member has clinical manifestations characteristic of achondroplasia (e.g. macrocephaly, frontal bossing, midface retrusion, disproportionate short stature with rhizomelic shortening of the arms and the legs, brachydactyly, trident configuration of the hands, thoracolumbar kyphosis, and accentuated lumbar lordosis), (ii) Member has radiographic findings characteristic of achondroplasia (e.g. large calvaria and narrowing of the foramen magnum region, undertubulated, shortened long bones with metaphyseal abnormalities, narrowing of the interpedicular distance of the caudal spine, square ilia and horizontal acetabula, small sacrosiatic notches, proximal scooping of the femoral metaphysis, and short and narrow chest)
<b>Age Restrictions</b>	(Achondroplasia) (Initial) (Reauth): Member is 5 years of age or older
<b>Prescriber Restrictions</b>	(Achondroplasia) (Initial) (Reauth): Prescribed by or in consultation with one of the following: (1) clinical geneticist, (2) endocrinologist, (3) a physician who has specialized expertise in the management of achondroplasia
<b>Coverage Duration</b>	(Initial) (Reauth): 12 months
<b>Other Criteria</b>	(Achondroplasia) (Reauth): (1) member has open epiphyses, (2) Documentation of positive clinical response to therapy [e.g. improvement in annualized growth velocity (AGV) compared to baseline].
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VUITY

## Products Affected

- VUITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Presbyopia) (Initial): (1) Diagnosis of presbyopia (2) Provider confirms valid clinical rationale, which excludes lifestyle choice, as to why patient is unable to use corrective lenses (e.g., eyeglasses or contact lenses)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Presbyopia) (Initial) (Reauth): prescribed by or in consultation with one of the following (1) Ophthalmologist, (2) Optometrist
<b>Coverage Duration</b>	(Initial): 3 months, (Reauth): 6 months
<b>Other Criteria</b>	(Presbyopia) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. improvement in near vision in low light conditions without loss of distance vision)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# WAKIX

## Products Affected

- WAKIX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Narcolepsy type 1: (1) Diagnosis of cataplexy with narcolepsy (Type 1). (2) ONE of the following: (a) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT), (b) prescriber provides justification confirming that a sleep study would not be feasible and (3) Symptoms of cataplexy are present. Narcolepsy (Type 2): (1) Diagnosis of excessive daytime sleepiness in Narcolepsy (Type 2). (2) ONE of the following: (a) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT), (b) prescriber provides justification confirming that a sleep study would not be feasible and (3) Inadequate response or inability to tolerate modafinil or armodafinil.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# XELJANZ

## Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, UC, PJI, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), Janus kinase (JAK) inhibitors or potent immunosuppressants (e.g. azathioprine, cyclosporine)
<b>Required Medical Information</b>	<p>Rheumatoid arthritis (RA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine), (3) Member had inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Cyltezo, Yuflyma) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine) (3) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Cyltezo, Yuflyma) or documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate at least ONE conventional therapy (e.g. corticosteroid, aminosalicylate, azathioprine or 6-mercaptopurine) (3) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira), adalimumab-adbm (Cyltezo, adalimumab-aaty (Yuflyma)) or documentation demonstrating that a trial may be inappropriate. Polyarticular Juvenile Idiopathic Arthritis (PJI) [applies to Xeljanz tablets/oral solution]: (1) Diagnosis of PJI. (2) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira), etanercept (Enbrel), adalimumab-adbm (Cyltezo), adalimumab-aaty (Yuflyma) ) OR documentation demonstrating that a trial may be inappropriate. (3) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine.</p>
<b>Age Restrictions</b>	(RA, PsA, UC, AS): Member is 18 years of age or older. (PJI): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	(RA, PJI, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (UC): Prescribed by or in consultation with a gastroenterologist.

PA Criteria	Criteria Details
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of ankylosing spondylitis. (2) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira), adalimumab-adbm (Cyltezo), adalimumab-aaty (Yuflyma), etanercept (Enbrel)) OR documentation that a trial may be inappropriate.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XENAZINE

## Products Affected

- *tetrabenazine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Tourette's Syndrome (TS): (1) Diagnosis of TS, (2) Member has tics associated with Tourette's syndrome, (3) Inadequate response or inability to tolerate haloperidol or risperidone. Chorea- Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(TS, CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD)(Initial, Reauth): Prescribed by or in consultation with a neurologist or a psychiatrist.
<b>Coverage Duration</b>	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (TS, CHD): Indefinite.
<b>Other Criteria</b>	(TD)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XERMELO

## Products Affected

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Carcinoid Syndrome Diarrhea (CSD)(Initial): (1) Diagnosis of carcinoid syndrome diarrhea, (2) Diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g. octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months, (3) Used in combination with SSA therapy
<b>Age Restrictions</b>	(CSD)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CSD)(Initial, Reauth): Prescribed by or in consultation with an Oncologist, Endocrinologist, or Gastroenterologist
<b>Coverage Duration</b>	(Initial): 12 months (Reauth): Indefinite
<b>Other Criteria</b>	(CSD)(Reauth): (1) Positive clinical response to Xermelo therapy, (2) Xermelo will continue to be used in combination with SSA therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XGEVA

## Products Affected

- XGEVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when: Prevention of Skeletal Related Events in Multiple Myeloma or Bone Metastases from Solid Tumors (MM-BMST) : (1) For prevention of skeletal related events in multiple myeloma or bone metastases from solid tumors. Giant Cell Tumor of the Bone (GCTB): (1) Diagnosis of GCTB. (2) Member is (a) adult or (b) adolescent that is skeletally mature. (3) Tumor is unresectable or surgical resection is likely to result in severe morbidity. Hypercalcemia of Malignancy Refractory to Bisphosphonates (HCMRB): (1) Diagnosis of HCMRB.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(GCTB, HCMRB): Prescribed by or in consultation with an urologist, oncologist or hematologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review. (All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XIFAXAN

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prophylaxis for Hepatic Encephalopathy (HE): (1) Diagnosis of hepatic disease with risk for hepatic encephalopathy (i.e., previous episode of hepatic encephalopathy, advanced liver disease, hepatocellular carcinoma), (2) Inadequate response or inability to tolerate lactulose. Irritable Bowel Syndrome (IBS): (1) Diagnosis of irritable bowels syndrome- diarrhea, (2) Inadequate response or inability to tolerate BOTH of the following: (A) ONE of the following: (i) ONE Tricyclic antidepressant or (ii)selective serotonin reuptake inhibitor and (B) dicyclomine (3): BOTH of the following: (A) Member does not exceed 3 total courses (42 days in total) of therapy, (B) Member experiences irritable bowel syndrome with diarrhea (IBS-D) symptoms. Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) (Initial): (1) Diagnosis of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(HE): Indefinite. (IBS): 2 weeks. (SBBO/SIBO): Initial and Reauth: 2 weeks.
<b>Other Criteria</b>	(SBBO/SIBO) (Reauth): (1) Documentation of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) recurrence following successful initial treatment
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XOLAIR

## Products Affected

- XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML
- XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary for: Moderate to Severe Persistent Allergic Asthma (PAA)(Initial): (1) DIAGNOSIS OF MODERATE TO SEVERE PERSISTENT ALLERGIC ASTHMA, (2) The individual has a positive skin test or in vitro reactivity to a perennial aeroallergen, (3) The individual has a baseline serum IgE level of between 30 IU/mL and 1300 IU/mL, (4) Inadequate response or inability to tolerate a combination of high-dose inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA). Chronic Urticaria (CU)(Initial): (1) DIAGNOSIS OF CHRONIC URTICARIA, (2) an inadequate response, contraindication or inability to tolerate ONE second-generation H1 antihistamine at the maximally tolerated dose in addition to ANY of the following: (a) leukotriene receptor antagonist (e.g. montelukast) (b) histamine H2-receptor antagonist (e.g. ranitidine, cimetidine, famotidine), (c) substituting to a different second-generation antihistamine, (d) systemic glucocorticosteroids or (e) cyclosporine, (3) will be used concurrently with an h1 antihistamine, unless there is contraindication or intolerance to H1 antihistamines. Nasal Polyps (NP)(Initial): (1) Diagnosis of nasal polyps. (2) Member will use concurrently with nasal corticosteroid. (3) Member had inadequate response or inability to tolerate an intranasal corticosteroid. (4) Member has a baseline serum IgE level of between 30 IU/mL and 1500 IU/mL
<b>Age Restrictions</b>	(PAA)(Initial, Reauth): Member is 6 years of age or older (CU)(Initial, Reauth): Member is 12 years of age and older (NP)(Initial, Reauth): Member is 18 years of age and older
<b>Prescriber Restrictions</b>	(PAA)(Initial, Reauth): Prescribed by or in consultation with an Allergist, Immunologist, or Pulmonologist. (CU)(Initial, Reauth): Prescribed by or in consultation with allergist/immunologist, dermatologist. (NP)(Initial, Reauth): Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or ENT specialist.
<b>Coverage Duration</b>	(Initial): 12 months. (Reauth): 12 months.

PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to Part B vs Part D review. (PAA)(Reauth): (1) documentaiton of positive clinical response to therapy (e.g. reduction in number of asthma exacerbations, improvement in forced expiratory volume in 1 second (FEV1), or decreased use of rescue medications). (CU)(Reauth): (1) Member's disease status has been re-evaluated since the last authorization to confirm the member's condition warrants continued treatment (2) member has experienced one or both of the following: (a) Reduction in intching severity from baseline (b) Reduction in number of hives from baseline. (NP)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction in nasal polyps score [NPS: 0-8 scale], improvement in nasal congestion/obstruction score [NCS: 0-3 scale]) (2) Used in combination with another agent for nasal polyps.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# XYREM

## Products Affected

- *sodium oxybate*
- XYREM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CN, EDSN (Initial, Reauth): Concurrent use of sedative hypnotics and alcohol
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy, (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible and (3) Inadequate response or inability to modafinil or armodafinil. (adult use only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CN, EDSN)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XYWAV

## Products Affected

- XYWAV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Inadequate response or inability to modafinil. Idiopathic Hypersomnia (IH) (Initial): (1) Diagnosis of Idiopathic Hypersomnia as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), (2) Symptoms of excessive daytime sleepiness (e.g. nap duration of longer than 60 minutes) are present
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CN, EDSN, IH)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months. (IH) (Reauth): (1) Documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZAVESCA

---

## Products Affected

- *miglustat*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Type 1 Gaucher's Disease (T1GD): (1) Diagnosis of mild to moderate T1GD, (2) enzyme replacement therapy is not a therapeutic option (e.g. because of allergy, hypersensitivity, or poor venous access).
<b>Age Restrictions</b>	(T1GD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZEPOSIA

## Products Affected

- ZEPOSIA
- ZEPOSIA 7-DAY STARTER PACK
- ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG & 0.46MG 0.92MG(21)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Multiple Sclerosis (MS): (1) Diagnosis of relapsing form of multiple sclerosis (MS) (e.g. clinically isolated syndrome, relapsing-remitting disease, secondary progressive disease, including active disease with new brain lesions) and inadequate response or inability to tolerate two of the following medications: (a) Avonex (interferon beta-1a), (b) Plegridy (peginterferon beta-1a), (c) Betaseron (interferon beta-1b), (d) Glatopa (glatiramer acetate), (e) Tecfidera (Dimethyl Fumarate), (f) Gilenya (fingolimod), (g) Aubagio (teriflunomide), or (h) Rebif (interferon beta 1a), OR documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of ulcerative colitis, (2) Inadequate response or inability to tolerate TWO of the following (a) Humira (b) Xeljanz/Xeljanz XR (c) Stelara (d) Rinvoq (e) Cyltezo, (f) Yuflyma OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(MS) (UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(UC): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZOKINVY

## Products Affected

- ZOKINVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hutchinson-Gilford Progeria Syndrome (HGPS): (1) Diagnosis of Hutchinson-Gilford Progeria Syndrome. (2) Member has a body surface are of 0.39 m2 or above. Processing-deficient Progeroid Laminopathies (PDPL): (1) For treatment of processing-deficient Progeroid Laminopathies. (2) One of the following: (a) Heterozygous LMNA mutation with progerin-like protein accumulation (b) Homozygous or compound heterozygous ZMPSTE24 mutations. (3) Member has a body surface are of 0.39 m2 or above
<b>Age Restrictions</b>	(HGPS, PDPL): Member is 12 months of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZTALMY

## Products Affected

- ZTALMY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(CDKL5): (1) Diagnosis of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (2) Documentation of mutation in the CDKL5 gene (3) member is experiencing motor seizures (e.g., bilateral tonic, generalized tonic-clonic, bilateral clonic, atonic, focal, or bilateral tonic-clonic) (4) Inadequate response or inability to tolerate two formulary anticonvulsants (e.g., valproic acid, levetiracetam, lamotrigine)
<b>Age Restrictions</b>	(CDKL5): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(CDKL5): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Approve if for continuation of therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZURZUVAE

## Products Affected

- ZURZUVAE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PPD): (1) Diagnosis of Postpartum depression (PPD) (2) Inadequate response or inability to tolerate (a) one generic Selective serotonin reuptake inhibitor (SSRI) (b) One generic Serotonin-Norepinephrine reuptake inhibitor (SNRI) (3) Medication will not be used for greater than 14 days
<b>Age Restrictions</b>	(PPD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	14 days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No





## Index

<i>abiraterone acetate</i> .....	128	BYLVAY (PELLETS).....	21
<i>adapalene external cream</i> .....	181	CABOMETYX.....	128
<i>adapalene external gel 0.3 %</i> .....	181	CALQUENCE ORAL TABLET.....	128
<i>adapalene-benzoyl peroxide external gel</i> .....	181	CAMZYOS.....	23
ADBRY.....	10	CAPLYTA.....	24
ADEMPAS.....	11	CAPRELSA.....	128
AIMOVIG.....	12	<i>carglumic acid oral tablet soluble</i> .....	25
AKEEGA.....	128	<i>carisoprodol oral</i> .....	81
ALECENSA.....	128	CAYSTON.....	26
ALUNBRIG.....	128	CERDELGA.....	27
ALYQ.....	139	<i>chlordiazepoxide-clidinium</i> .....	76
AMABELZ ORAL TABLET 0.5-0.1 MG.....	77	CHOLBAM.....	28
<i>ambrisentan</i> .....	99	CIBINQO.....	30
<i>amphetamine sulfate</i> .....	57	CIMZIA SUBCUTANEOUS KIT 2 X 200 MG.....	31
APOKYN SUBCUTANEOUS SOLUTION		CIMZIA SUBCUTANEOUS PREFILLED SYRINGE	
CARTRIDGE.....	15	KIT.....	31
<i>apomorphine hcl subcutaneous</i> .....	15	CINRYZE.....	33
ARALAST NP INTRAVENOUS SOLUTION		<i>clemastine fumarate oral syrup</i> .....	76
RECONSTITUTED 1000 MG.....	157	CLIMARA PRO.....	77
<i>armodafinil</i> .....	16	COMBIPATCH.....	77
AUGTYRO.....	128	COMETRIQ (100 MG DAILY DOSE) ORAL KIT	
AUSTEDO.....	17	80 & 20 MG.....	128
AUSTEDO XR.....	17	COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3	
AUSTEDO XR PATIENT TITRATION.....	17	X 20 MG & 80 MG.....	128
AUVELITY.....	18	COMETRIQ (60 MG DAILY DOSE).....	128
AYVAKIT.....	128	COPIKTRA.....	128
BALVERSA.....	128	CORLANOR.....	35
BENLYSTA SUBCUTANEOUS.....	19	CORTROPHIN.....	4
BERINERT.....	6	COSENTYX (300 MG DOSE).....	36
BESREMI.....	20	COSENTYX SENSOREADY (300 MG).....	36
<i>bexarotene</i> .....	128, 180	COSENTYX SUBCUTANEOUS SOLUTION	
BIJUVA.....	77	PREFILLED SYRINGE 75 MG/0.5ML.....	36
BIVIGAM INTRAVENOUS SOLUTION 5		COSENTYX UNOREADY.....	36
GM/50ML.....	88	COTELLIC.....	128
<i>bosentan</i> .....	182	CRESEMBA ORAL.....	37
BOSULIF.....	128	<i>cyclobenzaprine hcl er oral capsule extended</i>	
BRAFTOVI ORAL CAPSULE 75 MG.....	128	<i>release 24 hour 15 mg</i> .....	81
BRUKINSA.....	128	<i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg</i> .....	81
<i>butalbital-acetaminophen oral tablet 50-325</i>		CYLTEZO (2 PEN).....	8
<i>mg</i> .....	76	CYLTEZO (2 SYRINGE).....	8
<i>butalbital-apap-caff-cod</i> .....	76	CYLTEZO-CD/UC/HS STARTER.....	8
<i>butalbital-apap-caffeine oral capsule</i> .....	76	CYLTEZO-PSORIASIS/UV STARTER.....	8
<i>butalbital-apap-caffeine oral tablet 50-325-</i>		CYSTADROPS.....	38
<i>40 mg</i> .....	76	CYSTARAN.....	38
<i>butalbital-aspirin-caffeine oral capsule</i> .....	76	<i>dalfampridine er</i> .....	14
BYLVAY.....	21	DAURISMO.....	128

DAYBUE .....	39	<i>fentanyl citrate buccal lozenge on a handle</i> .....	63
DAYVIGO .....	40	<i>fentanyl transdermal patch 72 hour 100</i>	
<i>deferasirox granules</i> .....	41	<i>mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 62.5 mcg/hr,</i>	
<i>deferasirox oral tablet</i> .....	41	<i>87.5 mcg/hr</i> .....	74
<i>deferasirox oral tablet soluble</i> .....	41	<i>fentanyl transdermal patch 72 hour 50 mcg/hr,</i>	
<i>deferiprone</i> .....	64	<i>75 mcg/hr</i> .....	74
DIACOMIT .....	42	FERRIPROX ORAL SOLUTION .....	64
<i>dipyridamole oral</i> .....	76	FERRIPROX TWICE-A-DAY .....	64
DOJOLVI .....	43	FILSPARI .....	65
DOPTELET ORAL TABLET 20 MG .....	44	FINTEPLA .....	66
DOTTI .....	77	FIRDAPSE .....	67
DUPIXENT SUBCUTANEOUS SOLUTION PEN-		FORTEO SUBCUTANEOUS SOLUTION PEN-	
INJECTOR .....	45	INJECTOR 600 MCG/2.4ML .....	177
DUPIXENT SUBCUTANEOUS SOLUTION		FOTIVDA .....	128
PREFILLED SYRINGE 200 MG/1.14ML, 300		FRUZAQLA .....	128
MG/2ML .....	45	FYAVOLV .....	77
EMGALITY .....	47	GAMMAGARD INJECTION SOLUTION 2.5	
EMGALITY (300 MG DOSE) .....	47	GM/25ML .....	88
EMSAM .....	49	GAMMAGARD S/D LESS IGA .....	88
ENBREL MINI .....	50	GAMMAKED INJECTION SOLUTION 1	
ENBREL SUBCUTANEOUS SOLUTION 25		GM/10ML .....	88
MG/0.5ML .....	50	GAMMAPLEX INTRAVENOUS SOLUTION 10	
ENBREL SUBCUTANEOUS SOLUTION		GM/100ML, 10 GM/200ML, 20 GM/200ML, 5	
PREFILLED SYRINGE .....	50	GM/50ML .....	88
ENBREL SURECLICK SUBCUTANEOUS		GAMUNEX-C INJECTION SOLUTION 1	
SOLUTION AUTO-INJECTOR .....	50	GM/10ML .....	88
ENDARI .....	51	GATTEX .....	68
ENSPRYNG .....	52	GAVRETO .....	128
ENTYVIO SUBCUTANEOUS .....	53	<i>gefitinib</i> .....	128
EPCLUSA .....	142	GENOTROPIN MINIQUICK SUBCUTANEOUS	
EPIDIOLEX .....	54	PREFILLED SYRINGE 0.4 MG, 0.6 MG, 0.8 MG,	
ERIVEDGE .....	128	1 MG, 1.2 MG, 1.4 MG, 1.6 MG, 1.8 MG, 2 MG ...	69
ERLEADA .....	128	GENOTROPIN SUBCUTANEOUS CARTRIDGE 5	
<i>erlotinib hcl</i> .....	128	MG .....	69
ESBRIET .....	55	GILOTRIF .....	128
<i>estradiol transdermal</i> .....	77	GLEOSTINE ORAL CAPSULE 10 MG, 100 MG,	
<i>estradiol-norethindrone acet</i> .....	77	40 MG .....	128
<i>eszopiclone oral tablet 3 mg</i> .....	79	GRASTEK .....	13
EUCRISA .....	56	HAEGARDA .....	71
<i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5</i>		HARVONI ORAL PACKET .....	142
<i>mg</i> .....	128	HARVONI ORAL TABLET 90-400 MG .....	142
<i>everolimus oral tablet soluble</i> .....	128	HETLIOZ .....	72
EVRYSDI .....	58	HETLIOZ LQ .....	73
EXKIVITY .....	128	HUMIRA (2 PEN) .....	82
EYSUVIS .....	60	HUMIRA (2 SYRINGE) SUBCUTANEOUS	
FASENRA .....	61	PREFILLED SYRINGE KIT 10 MG/0.1ML, 20	
FASENRA PEN .....	61	MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML .....	82

HUMIRA-CD/UC/HS STARTER	KISQALI FEMARA (200 MG DOSE) .....	128
SUBCUTANEOUS PEN-INJECTOR KIT 80	KISQALI FEMARA (400 MG DOSE) .....	128
MG/0.8ML .....	KISQALI FEMARA (600 MG DOSE) .....	128
HUMIRA-PED .....	KORLYM .....	98
HUMIRA-PED>/=40KG CROHNS START .....	KOSELUGO .....	128
HUMIRA-PED>/=40KG UC STARTER .....	KRAZATI .....	128
HUMIRA-PSORIASIS/UVEIT STARTER .....	<i>lapatinib ditosylate</i> .....	128
<i>hydrocodone bitartrate er oral capsule</i>	<i>lenalidomide</i> .....	128
<i>extended release 12 hour</i> .....	LENVIMA (10 MG DAILY DOSE) .....	128
<i>hydromorphone hcl er oral tablet extended</i>	LENVIMA (12 MG DAILY DOSE) .....	128
<i>release 24 hour</i> .....	LENVIMA (14 MG DAILY DOSE) .....	128
<i>hydromorphone hcl oral tablet 4 mg, 8 mg</i> .....	LENVIMA (18 MG DAILY DOSE) .....	128
IBRANCE .....	LENVIMA (20 MG DAILY DOSE) .....	128
<i>ibuprofen-famotidine</i> .....	LENVIMA (24 MG DAILY DOSE) .....	128
<i>icatibant acetate subcutaneous solution</i>	LENVIMA (4 MG DAILY DOSE) .....	128
<i>prefilled syringe</i> .....	LENVIMA (8 MG DAILY DOSE) .....	128
ICLUSIG .....	LIBRAX .....	76
IDHIFA .....	<i>lidocaine external patch 5 %</i> .....	100
<i>imatinib mesylate</i> .....	LIVMARLI .....	101
IMBRUVICA ORAL CAPSULE .....	LIVTENCITY .....	102
IMBRUVICA ORAL SUSPENSION .....	LONSURF .....	128
IMBRUVICA ORAL TABLET 140 MG, 280 MG,	LORBRENA .....	128
420 MG .....	LUMAKRAS .....	128
INBRIJA .....	LUMRYZ .....	103
INCRELEX .....	LYLLANA .....	77
INGREZZA .....	LYNPARZA ORAL TABLET .....	128
INLYTA .....	LYTGOBI (12 MG DAILY DOSE) .....	128
INQOVI .....	LYTGOBI (16 MG DAILY DOSE) .....	128
INREBIC .....	LYTGOBI (20 MG DAILY DOSE) .....	128
ISTURISA ORAL TABLET 1 MG, 5 MG .....	MAVYRET .....	142
IWILFIN .....	MEKINIST .....	128
JAKAFI .....	MEKTOVI .....	128
JATENZO .....	MENOSTAR .....	77
JAYPIRCA .....	<i>metaxalone</i> .....	76
JINTELI .....	<i>metformin hcl er (mod) oral tablet extended</i>	
JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30	<i>release 24 hour 500 mg</i> .....	59
MG, 5 MG .....	<i>metformin hcl oral tablet 625 mg</i> .....	104
JYNARQUE ORAL TABLET THERAPY PACK .....	<i>methadone hcl oral solution</i> .....	74
KALYDECO .....	<i>methadone hcl oral tablet</i> .....	74
KERENDIA .....	<i>miglustat</i> .....	203
<i>ketorolac tromethamine oral</i> .....	MIMVEY .....	77
KEVZARA .....	<i>modafinil oral</i> .....	105
KINERET SUBCUTANEOUS SOLUTION	<i>morphine sulfate er beads oral capsule</i>	
PREFILLED SYRINGE .....	<i>extended release 24 hour 120 mg</i> .....	74
KISQALI (200 MG DOSE) .....	<i>morphine sulfate er oral capsule extended</i>	
KISQALI (400 MG DOSE) .....	<i>release 24 hour 100 mg, 60 mg, 80 mg</i> .....	74
KISQALI (600 MG DOSE) .....		

<i>morphine sulfate er oral tablet extended release</i>	ORENITRAM MONTH 3 .....	131
100 mg, 200 mg, 60 mg .....	ORGOVYX .....	128
MYALEPT .....	ORIAHNN .....	133
MYCAPSSA .....	ORKAMBI .....	134
MYFEMBREE .....	ORLADEYO .....	135
<i>naproxen-esomeprazole mg</i> .....	<i>orphenadrine-aspirin-caffeine oral tablet 25-</i>	
NAYZILAM .....	385-30 mg .....	80
NERLYNX .....	ORSERDU .....	128
NEXAVAR .....	OSPHENA .....	138
NEXLETOL .....	OTEZLA .....	136
NEXLIZET .....	OXBRYTA .....	137
NINLARO .....	<i>oxycodone hcl oral tablet 30 mg</i> .....	74
NORDITROPIN FLEXPPO SUBCUTANEOUS	<i>oxymorphone hcl er oral tablet extended release</i>	
SOLUTION PEN-INJECTOR .....	12 hour 20 mg, 30 mg .....	74
<i>norethindrone-eth estradiol</i> .....	<i>oxymorphone hcl er oral tablet extended release</i>	
NORGESIC .....	12 hour 40 mg .....	74
NOURIANZ .....	PANZYGA .....	88
NOXAFIL ORAL SUSPENSION .....	<i>pazopanib hcl</i> .....	128
NUBEQA .....	PEMAZYRE .....	128
NUCALA .....	PIQRAY (200 MG DAILY DOSE) .....	128
NUDEXTA .....	PIQRAY (250 MG DAILY DOSE) .....	128
NUPLAZID ORAL CAPSULE .....	PIQRAY (300 MG DAILY DOSE) .....	128
NUPLAZID ORAL TABLET 10 MG .....	<i>pirfenidone</i> .....	55
NURTEC .....	POMALYST .....	128
NUZYRA .....	<i>posaconazole oral</i> .....	115
OICALIVA .....	PRALUENT SUBCUTANEOUS SOLUTION	
OCTAGAM INTRAVENOUS SOLUTION 1	AUTO-INJECTOR .....	140
GM/20ML, 2 GM/20ML .....	PREMARIN ORAL .....	77
ODACTRA .....	<i>pretomanid</i> .....	143
ODOMZO .....	PRIVIGEN INTRAVENOUS SOLUTION 20	
OFEV .....	GM/200ML .....	88
OGSIVEO .....	PROCYSBI ORAL PACKET .....	144
OJJAARA .....	PROLASTIN-C INTRAVENOUS SOLUTION	
OLUMIANT ORAL TABLET 1 MG, 4 MG .....	RECONSTITUTED .....	157
OMNITROPE SUBCUTANEOUS SOLUTION	PROLIA SUBCUTANEOUS SOLUTION	
CARTRIDGE .....	PREFILLED SYRINGE .....	145
OMNITROPE SUBCUTANEOUS SOLUTION	PROMACTA .....	147
RECONSTITUTED .....	<i>promethazine hcl oral syrup</i> .....	76
ONUREG .....	<i>promethazine hcl oral tablet</i> .....	76
OPSUMIT .....	<i>promethazine hcl rectal suppository 12.5 mg,</i>	
OPZELURA .....	25 mg .....	76
ORALAIR .....	PROMETHEGAN RECTAL SUPPOSITORY 25	
ORENCIA CLICKJECT .....	MG, 50 MG .....	76
ORENCIA SUBCUTANEOUS SOLUTION	PYRUKYND .....	149
PREFILLED SYRINGE .....	PYRUKYND TAPER PACK .....	149
ORENITRAM MONTH 1 .....	QBREXZA .....	150
ORENITRAM MONTH 2 .....	QINLOCK .....	128

<i>quinine sulfate oral</i> .....	151	TABRECTA.....	128
RADICAVA ORS STARTER KIT.....	152	<i>tadalafil (pah)</i> .....	139
RASUVO SUBCUTANEOUS SOLUTION AUTO- INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML.....	87	<i>tadalafil oral tablet 2.5 mg, 5 mg</i> .....	29
RAVICTI.....	153	TADLIQ.....	171
RECORLEV.....	154	TAFINLAR.....	128
REPATHA.....	155	TAGRISSE.....	128
REPATHA PUSHTRONEX SYSTEM.....	155	TALTZ.....	173
REPATHA SURECLICK.....	155	TALZENNA.....	128
RETEVMO.....	128	TARPEYO.....	175
REVLIMID.....	128	TASIGNA.....	128
REZLIDHIA.....	128	<i>tasimelteon</i> .....	72
REZUROCK.....	158	<i>tavorole</i> .....	125
RINVOQ.....	159	TAVNEOS.....	176
ROZLYTREK ORAL CAPSULE.....	128	TAZVERIK.....	128
RUBRACA.....	128	TEPMETKO.....	128
RYDAPT.....	128	<i>teriparatide (recombinant) subcutaneous solution pen-injector 620 mcg/2.48ml</i> .....	177
SAJAZIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	6	<i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml</i> .....	179
SCEMBLIX.....	128	<i>testosterone enanthate intramuscular solution</i> .....	179
SIGNIFOR.....	162	<i>testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i> .....	179
<i>sildenafil citrate oral tablet 20 mg</i> .....	163	<i>testosterone transdermal solution</i> .....	179
SIRTURO.....	164	<i>tetrabenazine</i> .....	195
SIVEXTRO.....	112, 127	THALOMID.....	128
SKYCLARYS.....	165	TIBSOVO.....	128
SKYRIZI PEN.....	166	TLANDO.....	179
SKYRIZI SUBCUTANEOUS.....	166	<i>tolvaptan</i> .....	161
SKYTROFA.....	167	TRACLEER.....	182
<i>sodium oxybate</i> .....	201	TREMFYA.....	183
<i>sorafenib tosylate</i> .....	128	<i>tretinoin external</i> .....	181
SOVALDI ORAL PACKET.....	113	TRIKAFTA.....	184
SOVALDI ORAL TABLET 200 MG.....	113	TRUQAP.....	128
SPRYCEL.....	128	TUKYSA.....	128
STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML.....	168	TURALIO ORAL CAPSULE 125 MG.....	128
STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	168	TYMLOS.....	185
STIVARGA.....	128	TYVASO DPI MAINTENANCE KIT INHALATION POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG.....	186
<i>sunitinib malate</i> .....	128	TYVASO DPI TITRATION KIT INHALATION POWDER 16 & 32 & 48 MCG.....	186
SYMDEKO.....	169	UBRELVY.....	187
SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	170	VALCHLOR.....	180
SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	170	VALTOCO 10 MG DOSE.....	7
		VALTOCO 15 MG DOSE.....	7
		VALTOCO 20 MG DOSE.....	7

VALTOCO 5 MG DOSE.....	7	YUFLYMA (1 PEN) SUBCUTANEOUS AUTO-	
VANFLYTA.....	128	INJECTOR KIT 40 MG/0.4ML.....	8
VENCLEXTA.....	128	YUFLYMA (2 SYRINGE) SUBCUTANEOUS	
VENCLEXTA STARTING PACK.....	128	PREFILLED SYRINGE KIT 40 MG/0.4ML.....	8
VENTAVIS.....	188	ZEJULA ORAL TABLET.....	128
VERZENIO.....	128	ZELBORAF.....	128
VIJOICE.....	189	ZEMAIRA INTRAVENOUS SOLUTION	
VITRAKVI.....	128	RECONSTITUTED 1000 MG.....	157
VIZIMPRO.....	128	ZEMDRI.....	112
VONJO.....	128	ZEPOSIA.....	204
<i>voriconazole intravenous</i> .....	138	ZEPOSIA 7-DAY STARTER PACK.....	204
VOSEVI.....	113	ZEPOSIA STARTER KIT ORAL CAPSULE	
VOTRIENT.....	128	THERAPY PACK 0.23MG &0.46MG	
VOXZOGO.....	190	0.92MG(21).....	204
VUITY.....	191	ZOKINVY.....	205
VYNDAMAX.....	172	ZOLINZA.....	128
VYNDAQEL.....	172	<i>zolpidem tartrate er oral tablet extended</i>	
WAKIX.....	192	<i>release 12.5 mg</i> .....	79
WELIREG.....	128	<i>zolpidem tartrate oral tablet 10 mg</i> .....	79
XALKORI.....	128	ZTALMY.....	206
XELJANZ.....	193	ZURZUVAE.....	207
XELJANZ XR.....	193	ZYDELIG.....	128
XERMELO.....	196	ZYKADIA ORAL TABLET.....	128
XGEVA.....	197		
XIFAXAN ORAL TABLET 550 MG.....	198		
XOLAIR SUBCUTANEOUS SOLUTION			
PREFILLED SYRINGE 150 MG/ML, 75			
MG/0.5ML.....	199		
XOLAIR SUBCUTANEOUS SOLUTION			
RECONSTITUTED.....	199		
XOSPATA.....	128		
XPOVIO (100 MG ONCE WEEKLY) ORAL			
TABLET THERAPY PACK 50 MG.....	128		
XPOVIO (40 MG ONCE WEEKLY) ORAL			
TABLET THERAPY PACK 40 MG.....	128		
XPOVIO (40 MG TWICE WEEKLY) ORAL			
TABLET THERAPY PACK 40 MG.....	128		
XPOVIO (60 MG ONCE WEEKLY) ORAL			
TABLET THERAPY PACK 60 MG.....	128		
XPOVIO (60 MG TWICE WEEKLY).....	128		
XPOVIO (80 MG ONCE WEEKLY) ORAL			
TABLET THERAPY PACK 40 MG.....	128		
XPOVIO (80 MG TWICE WEEKLY).....	128		
XTAMPZA ER.....	3, 74		
XTANDI.....	128		
XYREM.....	201		
XYWAV.....	202		